Development and Evaluation of Mucoadhesive Properties - In Vitro and Ex Vivo Studies. by Suresh kumar, E
DEVELOPMENT AND EVALUATION OF MUCOADHESIVE
PROPERTIES - IN VITRO AND EX VIVO STUDIES.
A Dissertation submitted to
THE TAMILNADU Dr.M.G.R. MEDICAL UNIVERSITY
Chennai-600032
In partial fulfillment of the requirements for the award of degree of
MASTER OF PHARMACY
IN
PHARMACEUTICS
Submitted by
REG. NO: 26105410
Under the guidance of
Mr.K.MOHAN KUMAR., M.Pharm
   
                     DEPARTMENT OF PHARMACEUTICS
SWAMY VIVEKANANDHA COLLEGE OF PHARMACY
ELAYAMPALAYAM
TIRUCHENGODE-637205
TAMILNADU.
MAY -2012
SWAMY VIVEKANANDHA COLLEGE OF PHARMACY
Elayampalayam, Tiruchengode, 637205.
Namakkal (DT), Tamilnadu.
Phone: 04288-234417 (8lines).
Fax: 04288-234417.                                              
Dr. M.P.NARMADA, M.Pharm, Ph.D.,
Principal 
CERTIFICATE
          This is to certify that the Dissertation entitled “Development and Evaluation of
Mucoadhesive Properties - In vitro and Ex vivo Studies” submitted to The Tamilnadu
Dr.  M.G.R  Medical  University,  Chennai,  is  a  bonafide  project  work  of  Reg  No:
26105410 (E.SureshKumar) in the Department of pharmaceutics, Swamy Vivekanandha
College of Pharmacy, Tiruchengode for the partial fulfillment for the degree of Master of
Pharmacy  under  the  guidance  of  Mr.K.MOHAN  KUMAR,  M.Pharm  Swamy
Vivekanandha College of Pharmacy, Tiruchengode. 
                                                      
                                                                        Signature of the Principal
                                                             Dr. M.P.NARMADA, M.Pharm, Ph.D.
                           
SWAMY VIVEKANANDHA COLLEGE OF PHARMACY
Elayampalayam, Tiruchengode, 637205.
                                                        Namakkal (DT), Tamilnadu.
                                                                                           Phone: 04288-234417(8lines). 
                       Fax: 04288-234417.
Dr. N.N.RAJENDRAN, M.Pharm., Ph.D.,
Director of P.G Studies and Research
CERTIFICATE
          This is to certify that the Dissertation entitled “Development and Evaluation of
Mucoadhesive Properties - In vitro and Ex vivo Studies” submitted to The Tamilnadu
Dr.  M.G.R.  Medical  University,  Chennai,  is  a  bonafide  project  work  of Reg  No:
26105410   (E.Suresh  Kumar) in  the  Department  of  Pharmaceutics,  Swamy
Vivekanandha  College  of  Pharmacy,  Tiruchengode  for  the  partial  fulfillment  for  the
degree  of  Master  of  Pharmacy  under  the  guidance  of  Mr.K.MOHAN  KUMAR,
M.Pharm. Swamy Vivekanandha College of Pharmacy, Tiruchengode.
                                                             
                                                                                    Signature of Director of P.G. studies
Dr. N.N.RAJENDRAN, M.Pharm, Ph.D.                                          
  SWAMY VIVEKANANDHA COLLEGE OF PHARMACY
Elayampalayam, Tiruchengode, 637205.
                                                            Namakkal (DT), Tamilnadu.
                                                                                                           Phone: 04288-234417(8lines).
                                                                                                           Fax: 04288-234417.
R. NATARAJAN, M.Pharm, (Ph.D.),
Head Department of Pharmaceutics
CERTIFICATE
          This is to certify that the Dissertation entitled “Development And Evaluation of
Mucoadhesive Properties- In Vitro and Ex Vivo Studies” submitted to The Tamilnadu
Dr.  M.G.R.  Medical  University,  Chennai,  is  a  bonafide  project  work  of Reg  No:
26105410 (E.Suresh Kumar) carried out in   the Department of Pharmaceutics, Swamy
Vivekanandha  College  of  Pharmacy,  Tiruchengode  for  the  partial  fulfillment  for  the
degree  of  Master  of  Pharmacy  under  the  guidance  of  Mr.K.MOHAN  KUMAR,
M.Pharm, Swamy Vivekanandha College of Pharmacy, Tiruchengode.
                                                             
    Signature of Head Department of Pharmaceutics
                                                       R.NATARAJAN, M.Pharm, (Ph.D.)
                       
                
                                                         
 SWAMY VIVEKANANDHA COLLEGE OF PHARMACY
Elayampalayam, Tiruchengode, 637205.
                                                                                                           Namakkal (DT), Tamilnadu.
                                                                                                            Phone: 04288-234417(8lines).
                             Fax: 04288-234417.
K.MOHAN KUMAR, M.Pharm,
Department of Pharmaceutics
CERTIFICATE
          This is to certify that the Dissertation entitled “Development And Evaluation of
Mucoadhesive Properties - In vitro and Ex vivo Studies” submitted to The Tamilnadu
Dr.  M.G.R.Medical  University,  Chennai,  is  a  bonafide  project  work  of Reg  No:
26105410 (E.Suresh Kumar) carried out in   the Department of Pharmaceutics, Swamy
Vivekanandha  College  of  Pharmacy,  Tiruchengode  for  the  partial  fulfillment  for  the
degree of Master of Pharmacy under my direct guidance. 
          This work is original and has not been submitted earlier for the award of any other
degree or diploma of this or any other university. 
                                                                
                                      
                                                                                                Signature of the Guide 
                                                           K.MOHAN KUMAR., M.Pharm      
           
 
DEDICATED TO
MY
FATHER
&
MOTHER
ACKNOWLEDGEMENT
ACKNOWLEDGEMENT
              
               The Joyness, Satisfaction and euphoria that comes along with successful
completion of any work would be incomplete unless we mention names of the people
who made it possible, whose constant guidance and encouragement served as a beam of
light crowned out effects.
                First and foremost I express bow down before Lord Almighty for his splendid
blessings and care in completing my project work and through out my life till this very
second.
                I render my sincere thanks to our Honorable Chairman & Secretary, “Vidhya
Ratna”,Thiru. Dr. M.Karunanidhi, M.S., Ph.D, D.Litt.,” for providing all facilities for
my  study  and  rendering  his  noble  hand  in  the  upliftment  of  education  in  all  the
disciplines.
                I consider it  as a great  honor express my deep sense of gratitude and
indebtedness  to, Mr.K.Mohan  Kumar,  M.Pharm,  Department  of  Pharmaceutics,
Swamy Vivekanandha  College  of  Pharmacy,  Tiruchengode,  which  is  affiliated  to  the
Tamil  nadu  Dr.M.G.R.Medical  University,  Chennai,  for  his  valuable  suggestion,
remarkable guidance, constant encouragement and every scientific and personal concern
throughout the course of investigation and successful completion of this work.
                I  am elated  to  place  on  record  my profound sense  of  gratitude  to
Dr.N.N.Rajendran,  M.Pharm,  Ph.D,  Director  of  P.G.Studies  and  Research,
Dr.M.P.Narmadha,  M.Pharm,  Ph.D,  Principal  and  Prof.  Department  of  Pharmacy
Practice  and   Prof.  R.Natarajan,  M  Pharm,  (Ph.D),  Head  of  the  Department  of
Pharmaceutics,  and  I  thank   Mrs.M.Rangapriya  M.pharm,  Mrs.R.subhasini
M.pharm, for  rendering  her  voluntary  and  friendly  support  during  my  project.
Department of Pharmaceutics, for their constrictive ideas at each and every stage of the
project. 
                I express my immense gratitude and respect to  Dr.D.DachinaMoorthy,
M.Pharm, Ph.D, for providing  support to my work with their enormous knowledge and
guidance. 
               And I express my deep gratitude to  Mr.S.Chokkalingam, Administrative
officer who are the supportive pillar of our Swamy Vivekanandha group of Institutions
for their advices and efforts to improve our knowledge.
                It would be unwise if I forget to express my sincere thank and gratitude to
Prof.C.JothiManivannan,  M.Pharm,  (Ph.D),  Prof.  S.  Anand  Thangadurai,
M.Pharm,  Ph.D,  Mr.M.Jambulingam,  M.Pharm and  Mr.R.Senthil  Kumar,
M.Pharm,(Ph.D), Dept. of Pharmaceutical Chemistry for their immense support in all
the analytical aspects of my study. I also take this opportunity to thank Dr.M.Alvin Jose,
M.Pharm, Ph.D and all other staffs of the Dept. of Pharmacology. I express my sincere
thanks  to  Dr.U.Subhashini,  M.Pharm,  Ph.D,  all  other  staffs  of  the  Dept.  of
Pharmacognosy and all the Teaching and Non-teaching Staffs of my college.
I owe my gratitude and heartfelt thanks to Dr.T.Siva kumar M.Pharm, Ph.D
and Mr.M.Jagadeswaran M.Pharm, Dept. of pharmaceutical Analysis, Nandha College
of pharmacy for helping me to carry out the spectral studies.
   I take this pleasant opportunity to convey my thanks to  Mr.M.Sekhar, for their
help and support in all my laboratory tests. I also like to thank  Mr.S.Senthil Kumar,
System Engineer for his continuous help in utilizing the computer facilities and proper
completion of my work. I extend my thanks to the Library staffs T.Rajakumar, and Mrs
sharmila for helping me in reviewing the journals and necessary books.
                I owe my sincere thanks to my Parents, Brothers M.Siva kumar, R.moorthi,
friends who cared for my well-being and had spent their times in shaping my character,
conduct and my life.  Without their moral  support I  am nothing and I dedicate all my
achievements at their feet. 
 Friends are treasures to me and It is very difficult to overstate my thanks to all
my friends Anisha Das, Anumala Brahmini, Raga Keerthi, Anusha.K, M.Anuradha,
P.Thejaswi,  Sandeep.D.K,  Srihari.K,  Srividya.K . It  has  been my happiest  time to
study , discuss, laugh and play with them all.
                 I  am very thankful  to  my seniors  Mr.T.Sakthi  kumar.,  M.Pharm.,
Mrs.S.Revathi, M.Pharm for their valuable advice and support.
                I am happy to thank all my friends especially Nivas, Deeksha, Latha And my
room mates  V.Venkateswaran, Sella kumar and V.Manikandan.           
 Also, I would like to thank the  Tamil Nadu Dr. M.G.R.Medical University
for providing a nice environment for learning.
   I fell delighted to express my whole hearted gratitude to all those who gave their
helping hands in completing my course and my project successfully.
                                                                                                                              
E.Suresh kumar
Reg.No: 26105410                                         
INDEX
S.NO CONTENTS PAGE 
NO
1. INTRODUCTION 1-3
2. REVIEW OF LITERATURE 4-17
3. OBJECTIVE OF THE STUDY 18
4. PLAN OF WORK 19
5. PROFILES 20
5.1 DRUG PROFIE 20-23
5.2  POLYMER PROFILE 24-33
5.3  EXCIPIENT PROFILE 34-35
6. MATERIALS AND INSTRUMENTS 36-37
7. METHODOLOGY 38-52
8. RESULTS 53-127
9. DISCUSSION 128-129
10. CONCLUSION 130
11. BIBILIOGRAPHY 131-135

1. INTRODUCTION
Mucoadhesive controlled drug delivery systems are very beneficial,  since they
provide a controlled drug release over long period of time and localize the drug to a
specific site of the body. The prolonged residence time of the drug in the body is believed
to prolong duration of action. Mucoadhesive drug delivery system can be applied to any
mucosal  tissue  in  the  body.  Including the  gastrointestinal,  ocular,  respiratory,  buccal,
nasal, rectal, urethral and vaginal path.1
Mucoadhesion, defined as the ability to adhere to the mucus gel layer, is a key
element to design of these drug delivery systems. Mucus is composed of 95% water and
about 5% mucus glycoproteins termed mucin, plus a large number of minor components.2
Mucoadhesion  is  provided  by  the  formation  of  non-covalent  bonds  such  as
hydrogen bonds and ionic interactions or physical entanglements between the mucus gel
layer and polymers. Mediated by mucoadhesive polymers, the residence time of dosage
forms on the mucosa should be prolonged, which allows a controlled drug release at a
given target site to maximize the therapeutic effect.3 Several classes of polymers have
been  proposed  as  mucoadhesive  due  to  their  ability  to  interact  physically  and/or
chemically  with  the  mucus, such  as  hydrogen  bonds,  Van-Der  Waal  forces,  ionic
interactions and/or chain entanglements, which are the most common.2
Increasing the retention time (mucoadhesion time) of the dosage form is therefore
essential in the development of these systems and it has been shown to increase with an
increase in the mucoadhesivity of the system. Maximizing the mucoadhesivity of these
systems therefore remains an important goal in the development of mucoadhesive drug
delivery systems. In addition to mucoadhesivity, a controlled release of the drug from the
dosage  form  is  also  desirable.  The  potential  advantages  of  this  concept  include  the
minimisation of drug related side effects and improved patient compliance. 4
The oral cavity and oral mucosa is being increasingly used for the administration
of drugs, which are the oral disintegration and buccal/sublingual route of medicaments
into the systemic circulation.5 Rapid orally disintegrating tablets may be used to achieve a
fast  onset  of  action.   Alternatively,  the  buccal/sublingual  route  is  also  suitable  for
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medications that cannot or shall not be taken by the oral route due to instability of the
drug at the low pH of the stomach, or their susceptibility to the hepatic first pass effect.6
The buccal region of the oral cavity is an attractive target for administration of the
drug of choice. Buccal delivery involves the administration of the desired drug through
the buccal mucosal membrane lining of the oral cavity. The buccal mucosa, along with
other mucosal tissues, has been investigated as a potential site for controlled delivery
because of its accessibility and low enzymatic activity compared to the gastro-intestinal
tract. Another interesting advantage is its tolerance (in comparison with the nasal mucosa
and skin) to potential sensitizers. 7
Mucoadhesive  polymers  are  used  to  immobilize  a  drug  delivery  device  on  a
specific site for targeted release and optimal drug delivery due to intimacy and duration
of  contact.  Mucoadhesive  polymers  have  been  developed  for  buccal,  nasal,  ocular,
vaginal and oral applications. So far, a considerable number of studies focusing on the
mucoadhesive  properties of wide range of polymeric materials, particularly hydrophilic
polymers  containing numerous  hydrogen  bond (H-bond)   forming groups,  have  been
performed.  It  has  been  proposed  that  the  interaction  between  the  mucus  and
mucoadhesive  polymers  is  a  result  of  physical  entanglement  and secondary bonding,
mainly H-bonding and van der Waals attraction. These forces are related to the chemical
structure  of  the  polymers.  The  types  of  surface  chemical  groups  of  mucoadhesive
polymers that contribute to mucoadhesion include hydroxyl, carboxyl, amine and amide
groups in the structure.
There are many factors affecting the mucoadhesive properties of   polymers, such
as degree of hydration, ionic strength of medium & their molecular feature. The strategy
for  designing  buccoadhesive  is  based  principally on  the  utilization  of  polymers  with
suitable  physicochemical  properties.5 The  use  of  acrylic-based  polymers  can  be  very
beneficial  to  overcome  the  shortcomings  of  oral  drug  administration.  Acrylic-based
polymers have been extensively used for mucoadhesive applications, since they exhibit
very high adhesive bond strength in contact with tissues. Thus, they allow the localization
of the drug at the site of absorption.1
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Additionally, mucoadhesive properties of polyacrylic acid cross linked polymer
depending  on  the  physical  properties.  Example:  solution,  gel  forming  &  swelling
properties of carbopol are different due to types or characteristics of carbopol.5           
HPMC  is  well  known as  one  of  the  most  effective  mucoadhesive  polymers.
HPMC is a
hardly water-soluble polymer carrier with the ability to swell on contact with aqueous
solutions, creating a hydrocolloid gel mass on the external surface. This mass gradually
dissolves during time. Therefore, from such a system, the release of the active ingredient
is expected to be controlled by the dissolution rate of the polymer gel in mucus.8
Studying the performance of mucoadhesive polymers has become an increasingly
important  tool  for  designing  mucoadhesive  drug  delivery  system.  The  current  study
intends to assess the adhesive properties of different polymer ratios by using goat buccal
mucosa.9 
Direct  compressed  tablets  prepared  from  mucoadhesive  polymers  can  be
effectively utilized as vehicles for the delivery of various therapeutic molecules. In the
present  study  includes  development  and  evaluation  of  mucoadhesive  hydrophilic
compressed tablets for buccal delivery by using atorvastatin calcium as model drug.
Atorvastatin  calcium,  which  is  an  antihyperlipidemic  drug  with  low  water
solubility and high membrane permeability included in BCS II.  The formulations were
prepared by direct compression method and investigated for physicochemical adhesive
and release characteristics. 
3

2. REVIEW OF LITERATURE
2.1 REVIEW OF MUCOADHESIVE DRUG DELIVERY SYSTEM
              
Mucoadhesive drug delivery systems are the systems which utilize the property of
mucoadhesion of certain polymers, which become adhesive on hydration and hence can
be used for targeting a drug to a particular region of the body for extended period of time.
Bioadhesion is an integral phenomenon in which two materials, at least one of which is
biological  are  held  together  by  means  of  interfacial  forces.  In  the  case  of  polymer
attached to mucin layer of a mucosal tissue. The mucosal layer lines a number of regions
of the body including the nose, gastrointestinal tract, urogenital tract, the airways, the ear
and eye.10
2.1.1 MECHANISM OF MUCOADHESION            
Several theories have been put forward to explain the mechanism of polymer–
mucus interactions that lead to mucoadhesion. To start with, the sequential events that
occur during bioadhesion include an intimate contact between the bioadhesive polymer
and the biological tissue due to proper wetting of the bioadhesive surface and swelling of
the  bioadhesive.  The  polymer–water  interaction  becomes  greater  than  the  polymer-
polymer interaction, thereby making the polymer chains available for mucus penetration.
Following polymer hydration intermingling between chain segments of the mucoadhesive
polymer with the mucus occurs. The factors critical for this model of mucoadhesion are
the diffusion  coefficient  of  the polymer,  contact  time and  contact  pressure.  The  most
research has described bioadhesive bond formation as a three step process:-
STEP1: Wetting and swelling of polymer
STEP2: Interpenetration between the polymer chains and the mucosal membrane.  
STEP3: Formation of Chemical bonds between the entangled chains.11
4
Fig 1: The Two Steps of Mucoadhesive Process
Fig 2: Wetting and Swelling of Polymer
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2.1.2 ADVANTAGES OF BUCCAL DRUG DELIVERY
            
 Bypass  of  the  gastrointestinal  tract  and  hepatic  portal  system,  increasing  the
bioavailability of orally administered drugs that otherwise undergo hepatic first-
pass metabolism.
 Improved  patient  compliance  due  to  the  elimination  of  associated  pain  with
injections.
 A relatively rapid onset of action can be achieved relative to the oral route and the
formulation can be removed if therapy is required to be discontinued.
 Increased ease of drug administration
 The large contact surface of the oral cavity contributes to rapid and extensive drug
absorption.
 Extent of perfusion is more therefore quick and effective absorption.
 Nausea and vomiting are greatly avoided.
 Used in case of unconscious and less co-operative patients.
 Drugs, which show poor bioavailability via the oral route, can be administered
conveniently.
         Example: Drugs, which are unstable in the acidic environment of the stomach or
are destroyed by the enzymatic or alkaline environment of the intestine.
2.1.3 LIMITATIONS OF BUCCAL DRUG DELIVERY
 Drugs which irritate oral mucosa or have bitter taste, or cause allergic reactions,
discoloration of teeth cannot be formulated.
 If  formulation contains antimicrobial agents, affects the natural microbes in the
buccal cavity.
 The patient cannot eat/drink.
 Only those drugs which are absorbed by passive diffusion can be administered by
this route.
 Drugs which are unstable at buccal pH cannot be administered by this route.
 Swallowing  of  saliva  can  also  potentially  lead  to  the  loss  of  dissolved  or
suspended  drug  Low permeability of  the  buccal  membrane,  specifically when
compared to the sublingual membrane.11
2.2 OVERVIEW OF BUCCAL MUCOSA11
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A. Structure
FIG 3: CROSS SECTION OF ORAL MUCOSA
The oral mucosa is anatomically divided into 
 Epithelium
 Basement membrane and Connective tissues
Epithelium:  The  epithelium  consists  of  approximately  40–50  layers  of  stratified
squamous  epithelial  cells  having  thickness  500-800µm.  The  epithelium  of  the  oral
mucosa serves as a protective covering for the tissues and a barrier to the entry of foreign
materials. The uppermost layers form a surface that is resistant to physical insult and to
penetration by foreign substances. 
Basement Membrane and Connective Tissue:   The basement membrane (BM) is  a
continuous layer of extracellular materials and forms a boundary between the basal layer
of epithelium and the connective tissues. This basal complex anchors the epithelium to
the connective tissue and supplements the barrier function of the superficial layers of the
epithelium to prevent some large molecules from passing the oral mucosa.
7
B. Environment 
The oral  cavity is  marked by the presence  of  saliva produced by the salivary
glands and mucus which is secreted by the major and minor salivary glands as part of
saliva.
    Role of Saliva  
 Protective fluid for all tissues of the oral cavity.
 Continuous mineralization / demineralization of the tooth enamel.
 To hydrate oral mucosal dosage forms.
    Role of Mucus
 Made up of proteins and carbohydrates.
 Cell-cell adhesion.
 Lubrication.
 Bioadhesion of mucoadhesive drug delivery System.
2.3 TYPES OF MUCOADHESIVE DRUG DELIVERY SYSTEMS12
   1. Gastrointestinal bioadhesive drug delivery systems.
   2. Buccal bioadhesive drug delivery systems
        i. Adhesive tablets
       ii. Adhesive gels
     iii. Adhesive patches
   3. Sublingual bioadhesive drug delivery systems
   4. Ocular mucoadhesive drug delivery systems
   5. Nasal bioadhesive drug delivery systems
   6. Rectal bioadhesive drug delivery systems
   7. Vaginal bioadhesive drug delivery system
2.4  FACTORS  INFLUENCING  DRUG  ABSORPTION  FROM  THE  ORAL
CAVITY
As the oral mucosa is a highly vascular tissue, the main factors that influence drug
absorption from the mouth are:
  a)  The permeability of the oral mucosa to the drug.
  b)  Physicochemical characteristics of the drug.
8
  c)  Miscellaneous factors.
  d) Polymer-related factors.12
2.5 EVALUATION OF BUCCAL TABLETS13
♠ In vitro swelling rate and bioadhesion studies
♠  In vitro surface pH studies
♠ In vitro drug release studies
♠ In vitro permeation studies
♠ In vitro mucoadhesion strength
♠ In vitro residence time
♠ In vivo release studies
♠ Stability studies in human saliva
♠ Ex vivo mucoadhesion time
♠ Ex vivo mucoadhesion force
♠ Ex vivo transmucosal permeation studies
       
2.6 EXPERIMENTAL METHODOLOGY FOR BUCCAL PERMEATION 
STUDIES14
Before  a  buccal  drug  delivery  system  can  be  formulated,  buccal
absorption/permeation studies must be conducted to determine the feasibility of this route
of  administration  for  the  candidate  drug.  These  studies  involve  methods  that  would
examine in vitro and/or in vivo buccal permeation profile and absorption kinetics of the
drug.
A. In vitro permeation method     
At the present time, most of the in vitro studies examining drug transport across
buccal  mucosa  have used  buccal  tissues  from animal  models.  Animals  are  sacrificed
immediately  before  the  start  of  an  experiment.  Buccal  mucosa  with  underlying
connective tissue is surgically removed from the oral cavity, the connective tissue is then
carefully removed and the buccal mucosal membrane is isolated. The membranes are then
placed and stored in ice-cold (4°C) buffers (usually Krebs buffer) until mounted between
side-by-side diffusion cells for the in vitro permeation experiments. Buccal cell cultures
9
have  also  been  suggested  as  useful  in  vitro  models  for  buccal  drug  permeation  and
metabolism. However, to utilize these culture cells for buccal drug transport, the number
of differentiated cell layers and the lipid composition of the barrier layers must be well
characterized and controlled. 
B. In vivo Methods 
           In this method the kinetics of drug absorption was measured. The methodology
involves the swirling of a 25 ml sample of the test solution for up to 15 minutes by
human  volunteers  followed  by  the  expulsion  of  the  solution.  The  amount  of  drug
remaining in the expelled volume is then determined in order to assess the amount of
drug  absorbed.  The  drawbacks  of  this  method  include  salivary dilution  of  the  drug,
accidental swallowing of a portion of the sample solution, and the inability to localize the
drug solution within a specific site (buccal, sublingual, or gingival) of the oral cavity.
Other in vivo methods include those carried out using a small perfusion chamber attached
to the upper lip of anesthetized dogs. The perfusion chamber is attached to the tissue by
cyanoacrylate  cement.  The  drug  solution  is  circulated  through  the  device  for  a
predetermined period of time and sample fractions are then collected from the perfusion
chamber (to determine the amount of drug remaining in the chamber) and blood samples
are drawn after  0  and 30 minutes  (to determine amount of  drug absorbed across  the
mucosa).
2.7 MUCOADHESIVE POLYMERS10:
             Mucoadhesive polymers are water soluble and water insoluble polymers which
are  swellable  networks  jointed  by  cross  linking  agents.  An  ideal  polymer  for  a
mucoadhesive drug delivery system should have the following characteristics.
  1. The polymer and its degradation products should be nontoxic and non absorbable in
the gastrointestinal tract.
  2. It should be nonirritant to the mucus membrane.
  3. It should preferably form a strong non covalent bond with the mucin epithelial cell
surface.
  4. It should adhere quickly to moist tissue and should possess some site specificity.
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  5. It should allow easy incorporation of the drug and offer non hindrance to its release.
  6. The polymer must not decompose on storage or during shelf-life of the dosage form.
  7. The cost of polymer should not be high.
Some of the mucoadhesive polymers along with their mucoadhesive property are
summarized below:
Table 1: Mucoadhesive polymers with their mucoadhesive property
1 Carbopol 934  +++
2 Carboxy methyl cellulose  +++
3 Polycarbophil +++
4 Tragacanth +++
5 Sodium alginate  +++
6 Hydroxy ethyl cellulose  +++
7 Hydroxy propyl methyl cellulose  +++
8 Gum karaya  ++
9 Guar gum  ++
10 Poly vinyl pyrrolidone +
11 Polyethylene glycol  +
          Note: +++ excellent, ++ fair, +poor
2.8 INNOVATIVE DRUG DELIVERY SYSTEMS
           Innovative drug delivery systems, such as lipophylic gel,  buccal  spray and
phospholipid  vesicles  have  been  recently proposed to  deliver  peptides  via  the buccal
route. In particular, some authors proposed the use of cubic and lamellar liquid crystalline
phases of glyceryl monooleate as buccal drug carrier for peptide drugs. A novel liquid
aerosol formulation (Oralin, Generex Biotechnology) has been recently developed, and it
is now in clinical phase II trials. This system allows precise insulin dose delivery via a
metered dose inhaler in the form of fine aerosolized droplets directed into the mouth.
Levels  of  drug  in  the  mouth  are  dramatically  increased  compared  with  conventional
technology. This oral aerosol formulation is rapidly absorbed through the buccal mucosal
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epithelium, and it provides the plasma insulin levels necessary to control postprandial
glucose rise  in  diabetic  patients.  This novel,  pain-free,  oral  insulin  formulation has  a
number of advantages including rapid absorption, a simple (user-friendly) administration
technique,  precise dosing control  (comparable to injection within one unit)  and bolus
delivery of drug. 
         Phospholipid deformable vesicles, transfersomes, have been recently devised for the
delivery of insulin in the buccal cavity. They are morphologically similar to liposomes,
but have the peculiarity of responding to external stresses by rapid shape transformations
requiring  low  energy.  This  high  deformability  allows  them  to  deliver  drugs  across
epithelial  barriers.  To  prepare  these  vesicles,  surfactants,  such  as  sodium  cholate  or
sodium  dehoxy  cholate  are  incorporated  into  the  vesicular  membrane.  The  insulin
administration in rabbits surpasses that seen with traditional liposomes: compared with
subcutaneous administration of insulin solution, the bioavailability of deformable vesicles
was  significantly  greater  than  that  of  the  conventional  vesicles.  It  is  necessary  to
underline that several formulations described here have been tested in animal models that
possess  buccal  mucosa  different  to  that  of  human.  For  such  formulations,  more
significant information could be derived from tests performed on other animal models
that better simulate humans or in human volunteers.15
REVIEW OF RELEVANT WORKS
G. Ikinci et al. developed a bioadhesive buccal tablet for the delivery of nicotine
into the oral  cavity.  Carbomer and alginic acid sodium salt were used as bioadhesive
polymers in combination with hydroxy propyl methylcellulose at different ratios. In vitro
release  and  bioadhesion  studies  were  performed  on  the  developed  tablets.  In  the
formulations  containing  CP:  HPMC,  the  NHT release  increased  with  the  increasing
HPMC  concentration  whereas  a  decrease  was  observed  with  increasing  HPMC
concentration in formulations containing NaAlg: HPMC. The bioadhesive properties of
the tablets containing NaAlg:HPMC was not affected by the concentration of the NaAlg
but  increased  significantly  with  the  increasing  CP  concentration.  The  developed
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formulations released NHT for 8 h period, and remained intact except for the formulation
containing CP: HPMC at 20:80 ratio.16
S.  S  enel  et  al. designed a bioadhesive tablet  formulation for  buccal  delivery
using a  mixture of  hydroxypropyl  methylcellulose and carbomer,  incorporated with a
penetration enhancer, sodium glycodeoxycholate (GDC). In vitro bioadhesion property of
the formulated tablet was examined and histological study was carried out to examine an
in vivo interaction between the tablet and tissue. GDC did not affect the adhesiveness of
the tablet which makes it an acceptable excipient for a buccal bioadhesive drug delivery
system. Histological changes such as loss of upper cell layers and formation of vacuoles
as well swelling in the cells were observed in the buccal epithelium, after 4 h contact with
the tablets containing GDC.17
Mahalaxmi D.  et  al. formulated and evaluated buccal  tablets of  glipizide,  an
antidiabetic drug. Tablets of glipizide were prepared by direct compression method using
bioadhesive  polymers  like  Carbopol  974P,  Methocel  K4M  and  Methocel  K15M  in
different concentrations. Buccal tablets were evaluated by different parameters such as
thickness, hardness, weight uniformity, content uniformity, swelling index, surface pH,
ex vivo  bioadhesive strength,  in vitro  drug release,  ex vivo  drug permeation and FTIR
studies. The tablets were evaluated for in vitro release in pH 6.8 phosphate buffer for 8 hr
in standard dissolution apparatus.  The optimized formula followed non-fickian release
mechanism with zero order kinetics. MethocelK15M in the ratio of 1:2 could be used to
design effective and stable buccoadhesive tablets of glipizide.18
C.F. Wong et al. carried out a study for measuring the bioadhesive properties of
polymers  under  simulated  buccal  conditions  by  a  method  using  a  texture  analyzer
equipment and chicken pouch as the biological tissue. The method was evaluated using
two polymers,  namely Carbopol  974P and Methocel  K4M. The parameters  measured
were the work of adhesion and peak detachment force. When the method was applied to
determine the bioadhesiveness of several polymers, the values obtained for the work of
adhesion and peak detachment force were quite consistent in the ranking of the polymers.
The  Carbopol  were  found  to  have  the  highest  values,  followed  by  gelatin,  sodium
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carboxymethyl  celluloses  and  hydroxypropylmethyl  celluloses.  On  the  other  hand,
Alginic acid, Eudragit RLPO and RSPO, and Chitosan appeared to have low bioadhesive
values.19
L.  Perioli  et  al.  prepared  mucoadhesive  tablets  using  different  mixture  of
cellulose  and  polyacrylic  derivatives  in  order  to  obtain  new formulations  containing
metronidazole  for  periodontal  disease  treatment.  All  the  prepared  tablets  were
characterized  by  swelling  studies,  ex  vivo  and  in  vivo  mucoadhesive  time,  ex  vivo
mucoadhesion force, in vitro and in vivo release. The best mucoadhesive performance
and the best in vitro drug release profile were achieved by using hydroxyethyl cellulose
and  carbomer  940  2:2  ratio.  The  chosen  tablet,  containing  20  mg of  metronidazole,
performed 12 h drug sustained release with buccal concentrations always higher than its
Minimum Inhibitory Concentration.20
N.A. Nafee et al. prepared and evaluated mucoadhesive patches containing 10 mg
miconazole  nitrate.  The  patches  were  prepared  with  ionic  polymers,  sodium
carboxymethyl cellulose (SCMC) and chitosan, or non-ionic polymers, polyvinyl alcohol
(PVA),  hydroxyethyl  cellulose  (HEC)  and  hydroxypropylmethyl  cellulose.  Patches
exhibited sustained release over more than 5 h and the addition of polyvinyl pyrrolidone
(PVP) generally enhanced the release rate. Optimum release behavior was shown with
patches containing 10% w/v PVA and 5% w/v PVP. In vivo release study concluded that
this formulation has  uniform and effective salivary levels with  adequate comfort  and
compliance during at least 6 hours.21
C. Remunan-Lopez et al. carried out a study describing the preparation of new
buccal bilayered devices comprising a drug-containing mucoadhesive layer and a drug-
free  backing layer,  by two different  methods.  Bilaminated films were produced by a
casting /  solvent  evaporation technique  and bilayered tablets  were obtained  by direct
compression. The mucoadhesive layer was composed of a mixture of drug and chitosan,
with or without an anionic crosslinking polymer (polycarbophil, sodium alginate, gellan
gum),  and  the  backing  layer  was  made  of  ethylcellulose.  Using  nifedipine  and
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propranolol hydrochloride as slightly and highly water-soluble model drugs, respectively,
it was demonstrated that these new devices show promising potential for use in controlled
delivery  of  drugs  to  the  oral  cavity.  The  uncrosslinked  chitosan-containing  devices
absorbed a large quantity of water, gelled and then eroded, allowing drug release. The
bilaminated films showed a sustained drug release in a phosphate buffer  of pH 6.4.22
S. Mohammadi-Samani et al. determined the effect of mucoadhesive polymers
such as hydroxyl propyl methyl cellulose with viscosity grade 60 and 500 mPas, sodium
carboxy methyl cellulose and carbopol 934 alone or in combination with each other on
the release profile  of  prednisolone and evaluated the mucoadhesion  strength  of  these
buccoadhesive formulations. The results showed that the release of prednisolone from
HPMC with viscosity grade 60 mPas and Cp 934 alone was fast and their mucoadhesion
strengths was low. On the other hand, the release rates of prednisolone from the HPMC
viscosity grade 500 mPas and NaCMC and mucoadhesion strengths were moderate and
suitable.  The results  showed that  with different  blends of HPMC viscosity grade 500
mPas  or  NaCMC and  Cp 934 with  increasing in  HPMC or  NaCMC/Cp 934  ratio  a
remarkable  decrease  in  the  rate  of  drug  release  and  an  appreciable  increase  in  the
mucoadhesion strength was observed.23
H.G. Choi et al. studied the release and bioavailability of omeprazole delivered
by buccal adhesive tablets composed of sodium alginate, hydroxypropylmethylcellulose,
magnesium oxide and croscarmellose sodium for the development of omeprazole buccal
adhesive  tablets.  The  analysis  of  the  release  mechanism showed  that  croscarmellose
sodium  changed  the  release  profile  of  omeprazole  from  first-  to  zero-order  release
kinetics  by forming porous  channels  in  the tablet  matrix.  The  tablet  is  composed  of
omeprazole–sodium  alginate–HPMC–magnesium  oxide–croscarmellose  sodium
(20:24:6:50:10  mg).  It  may be  attached  to  the  human  cheek  without  collapse  and  it
enhanced the stability of omeprazole in human saliva for at least 4 h, giving a fast release
of  omeprazole.  The buccal  bioavailability of omeprazole in hamsters  was 13.763.2%.
Thus the in vivo results demonstrated that the omeprazole buccal adhesive tablet would
be useful to deliver omeprazole which degrades very rapidly in acidic aqueous medium
and undergoes hepatic first-pass metabolism after oral administration..24
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E. Karavas  et  al. prepared  a pulsatile  release  formulation consisting of  two-
layered  tablets.  The  active  core  was  constituted  by  a  FELO/PVP 10/90  w/w  solid
dispersion  while  for  the  adjustment  of  the  drug  release  time  the  coating  layer  was
composed  of  PVP/HPMC  blends  at  different  compositions,  acting  as  a  stimulus
responsible layer. The miscibility of the system enhances the mucoadhesive properties of
the blends, compared with those of pure HPMC, which is desired for such applications.
The enhancement was attributed to the higher rate of wetting and flexibility of the new
matrices due to the faster dissolution of the PVP macromolecules. Upon exposure of the
prepared tablets to the release medium it was found that the coating layer disintegrates
first, followed by the immediate release of FELO from the active core.25
A.P. Munasur et al. carried out the statistical optimization of mucoadhesivity and
characterization  of  multi  polymeric  propranolol  matrices  for  buccal  therapy.  A
formulation of 20% PAA, 20% CMC and 20% PVP was identified for maximizing the
mucoadhesivity. Reproducibility of the optimal formulation in terms of mucoadhesivity
and controlled drug release was confirmed. The optimal formulation was characterized in
terms  of  mucoadhesivity,  release  kinetics,  swelling/erosion,  hydration  dynamics  and
surface pH. From the model fitting analyses,  drug release was found to be diffusion,
polymeric relaxation and erosion based with the former two being more dominant over
erosion. Textural profiling showed initial rapid hydration, which could be beneficial for
enhanced  mucoadhesivity.  Surface  pH of  the  multipolymeric  matrices  was  similar  to
salivary pH and did not show extremes in changes over  the test  period.  The optimal
preparation  of  multipolymeric  propranolol  matrices  identified  in  this  study  shows
potential for buccal administration.26
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3. AIM AND OBJECTIVE
        Atorvastatin calcium is a antihyperlipidemic drug comes under the BCS Class II
(low solubility and high permeability). It is known to have low oral bioavailability (14%)
due to extensive high first-pass effect and its availability in less dose. In order to maintain
the therapeutic concentration of atorvastatin calcium, modified release formulation are
necessary.    
          In the present work the mucoadhesive buccal tablets of atorvastatin calcium was
prepared to prolong the residence time at the site of application (or) absorption, and to
facilitate  the intimate contact  with the underlying absorption surface to improve and
enhance the mucoadhesive properties.
            The mucoadhesive buccal tablets of atorvastatin calcium were prepared by using
Carbopol-934, Hydroxy propyl methyl cellulose K100M, Hydroxy ethyl cellulose and
Polyvinylpyrolidone along with ethyl cellulose as an impermeable backing layer. 
          The most important goals in development and evaluation of mucoadhesion study
consist of drug targeting at specific site of absorption, controlled releasing, increasing of
residence time, decreasing   the first pass effect and long term drug delivery. 
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5. PROFILES
5.1 DRUG PROFILE
 ATORVASTATIN CALCIUM 27,28
Synonyms               :  Atorvastatina calcica,  
                                    Atorvastatine calcique, 
                                    Atorvastatinum calcicum; Calcii,       
               Atorvastatinum; CI-98.       
Category                   : Antihyperlipidemic agent
Empirical formula  : C66H68CaF2N4O10.3H2O
Molecular weight    :  1209.4
Chemical Name       : Calcium -2-(p-fluorophenyl)-beta, delta-dihydroxy-5-isopropyl-3-
phenyl-4-               
                                    (Phenylcarbamoyl) pyrrole-1-heptanoic acid (1:2) trihydrate.
Structure formula  :
Functional Category : HMG-CoA reductase inhibitors .
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Physicochemical properties
BCS classification   : Class II (low solubility and high permeability).
Description 
Atorvastatin calcium is a white to off-white crystalline powder that is insoluble in
aqueous solutions of pH 4 and below. Atorvastatin calcium is very slightly soluble in
distilled water, pH 7.4 phosphate buffer, and acetonitrile, slightly soluble in ethanol, and
freely soluble in methanol.
Clinical Pharmacology   
 Atorvastatin calcium is used along with diet, exercise, and weight-loss to reduce
the risk of heart attack and stroke and to decrease the chance that heart surgery will be
needed in people who have heart disease or who are at risk of developing heart disease.
Atorvastatin is also used to decrease the amount of cholesterol (a fat-like substance) and
other fatty substances in the blood. This will decrease the risk of stroke, heart attack, and
other heart diseases because when there are high levels of cholesterol and other fats in the
blood, these substances may build up along the walls of the blood vessels and decrease or
block blood flow to the heart. Atorvastatin is in a class of medications called HMG-CoA
reductase inhibitors (statins).  It  works by slowing the production of cholesterol in the
body.
Pharmacokinetics
Absorption
             Rapidly absorbed; T max   is 1 to 2h. Bioavailability is approximately 14%; low
bioavailability is because of presystemic circulation in GI mucosa and/or hepatic first-
pass metabolism. Food decreases rate and extent of absorption approximately 25% and
9%, respectively, but does not alter efficacy.
21
Distribution
            Mean  volume of  distribution of  atorvastatin  is  approximately 381 liters.
Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately
0.25 indicates poor drug penetration into red blood cells.
Metabolism
           Undergoes hepatic and extra hepatic metabolism, including first-pass metabolism.
Extensively metabolized  to  active  metabolites,  which  produce  approximately 70% of
circulating inhibitory activity of  HMG-Co A reductase.
Elimination
         Atorvastatin and metabolites eliminated primarily in bile. Less than 2% of dose is
recovered in the urine. Plasma t ½ is approximately 14 hours.
Duration
           The t ½ of HMG-CoA reductase inhibition is 20 to 30 hours.
Contraindications
Active liver disease or unexplained persistent elevation of serum transaminases;
pregnancy; lact. 
Dosage and Administration
Adults                                   
          10 to 80 mg/day.
Heterozygous Familial Hypercholesterolemia Children 10 to 17 yr of age 
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         Start with 10 mg/day (max, 20 mg/day).
Pharmacodynamics
Adverse Reactions
           CNS                    : Headache, Asthenia, dizziness, insomnia.
           ENT                    : Sinusitis, Pharyngitis, Rhinitis.
           Dermatologic     : Rash, Stevens-Johnson syndrome,
                     bullous rashes including erythema multiforme
                                           Toxic epidermal necrolysis.
          GI                        : Sinusitis, abdominal pain, constipation, dyspepsia, Nausea.
          Genitourinary    : Albuminuria, Hematuria.
          Metabolic            : Peripheral edema (at least 2%).
          Musculoskeletal : Myalgia, Arthralgia, Arthritis, Rhabdomyolysis.
          Respiratory         : Bronchitis.
          Miscellaneous     : Accidental injury, flu-like symptoms, chest pain, Angioneurotic 
                                         edema.
Drug Interactions
           Co Administration of Antacids, cholesterol, rifampin may decrease atorvastatin
levels.  Azole antifungal agents (eg, itraconazole), cyclosporine, diltiazem, gemfibrozil,
grapefruit  juice,  macrolide  antibiotics  (eg,  erythromycin),  niacin,  NNRTIs,  protease
inhibitors (eg, ritonavir), verapamil, severe myopathy or rhabdomyolysis may occur. 
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5.2 POLYMER PROFILE
5.2.1 CARBOPOL 934P29
Nonproprietary names : BP: Carbomer
  USP: Carbomer
Synonym : Acritamer, Acrylic acid polymer, Carboxy vinyl polymer,
carboxypolymethylene.
Chemical name : prop-2-enoic acid.
Molecular formula : C3H4O2
Structure :
Molecular weight :  700 000 to 4 billion.
Functional category : Bioadhesive  material,  emulsifying  agent,  suspending
agent, stabilizing agent, control-release agent, tablet binder,
viscosity-enhancing agent.
Description : White  colored,  fluffy,  acidic,  hygroscopic  powder  with
slightly characteristic odor.
Typical properties
Density        Bulk : 0.2 to 0.4 g/cm3 
                                Tapped   : 0.3 to 0.4 g/cm3
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Melting point : Within 30 minutes at 260ºC.
Glass transition temperature: 100 to 105ºC.
Specific gravity : 1.41
Viscosity : 38850 Cps
Hygroscopicity : Typical water content is up to 2% w/w.  Typical moisture 
content at 25ºC and 50% relative humidity is 8 to 10% w/w.
Solubility 
It is swellable in water and glycerin and after neutralization in ethanol 95%.  They
do not dissolve but merely swell to a remarkable extent.
Stability 
Carbomers are stable, hygroscopic materials that may be heated at temperature 
below 104ºC for up to 2 hours without affecting their thickening efficiency.  
Microorganisms may grow in unpreserved aqueous dispersions.
Storage 
In an airtight, corrosion-resistant container and protected from moisture.  The use 
of glass, plastic, or resin-lined containers is recommended for the storage.
Incompatibilities 
Incompatible with phenol, cationic polymers, strong  acids, and high levels of 
electrolytes.  They also form pH-dependent complexes with certain polymeric excipients.
Safety
It is essentially nontoxic and nonirritant material. Low oral toxicity is observed.  
No evidence in humans of hypersensitivity reactions.
Regulatory status
It is included in FDA Inactive Ingredients Guide.  Included in Canadian list of 
Acceptable Non-medicinal ingredients.
Applications
As rheology modifiers, controlled release agents or binders, emulsifying agents, 
viscosity-increasing aid, and also used in cosmetics.
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5.2.2 HYDROXY PROPYL METHYL CELLULOSE30
Non-Proprietary Names:  BP  : Hypromellose, 
                                USP: Hydroxy propyl methyl cellulose,
Synonyms                       : Methyl hydroxyl propyl cellulose, propylene glycol ether of    
        methyl cellulose, methylcellulose, methylcellulose propylene
glycol 
                                          ether.
Chemical Name        :    Cellulose, 2-Hydroxypropyl-Methyl Ether 
Empirical Formula  :     C8H15O6 – (C10H18O6)N – C8H15O5
Structure               
Molecular Weight   : Approximately 10,000–1,500,000. 
Density                     : 0.25 – 0.70 g/cm3
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Functional Category
Coating agent, film former, tablet binder, viscosity increasing agent, stabilizing
agent, suspending agent.                             
Solubility
Soluble in cold water forming viscous colloidal solution, insoluble in chloroform,
ethanol and ether, But Soluble n mixtures of ethanol and methylene chloride. 
Viscosity (dynamic)
Methocel Product       USP 28 Designation     Nominal Viscosity(Mpas)
     HPMC 5cps                           2208                                            5000
 Methocel K100M             2208                                            100000
Stability and Storage
It is stable although it is slightly hygroscopic. The bulk material should be stored
in airtight container in a cold and dry place. Increase in temperature reduces the viscosity
of the solution. 
Safety
It is  widely used  in  many oral  and  topical  pharmaceutical  formulations.  It  is
generally  regarded  as  a  non-toxic  and  non-irritant  material,  although  excessive
consumption may have laxative effect.
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5.2.3 HYDROXY ETHYL CELLULOSE31
Nonproprietary Names
                       BP: Hyroxy ethyl cellulose
                     USP: Hydroxy Ethyl cellulose
Synonyms                  : Alcoramnosan
                              Cellosize
                              Cellulose hydroxyl ethyl ether
                               HEC.
Chemical name        : Cellulose-2-hydroxy ethyl ether.                    
Structural formula:
Functional category:   Coating agent, suspending agent, tablet binder, thickening  
                                        agent, viscosity increasing agent.
Descriptions              :  It occurs as a light tan or cream to white  coloured odorless
                                       and  Tasteless powder. 
Typical properties   
Acidity/Alkalinity   :  pH 5.5-8.5 for a 1%w/v aqueous solution.
Density (bulk)          :   0.35-0.61 g/cm3
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Melting point            :   Softens at 135-140 degree Celsius, decomposes at about    
                                        205 degree Celsius.
Moisture content     : Commercially available grades contain less than 5 %w/w of
                                      water.                    
Solubility                
 It  is soluble in either hot or cold water, forming clear, smooth, uniform
solutions. Practically insoluble in acetone, ethanol, ether, toluene and most other
organic solvents.                  
Applications
              Hydroxy ethyl cellulose is a non ionic, water soluble polymer widely used in
pharmaceutical formulations. It is primarily used as a thickening agent in ophthalmic and
topical formulations.
Stability and Storage conditions
             It should be stored in a well closed container, in a cool, dry, place.
5.2.4 POLYVINYLPYRROLIDONE32
Synonyms                   : Poly [1-(2-oxo-1-pyrrolidinyl) ethylene]
                                      Polyvidone; polyvinylpyrrolidone,
                                     PVP,
                                     1-vinyl-2-pyrrolidinone polymer.
 Chemical Name      :   1-Ethenyl-2-pyrrolidinone homopolymer.
Empirical Formula:   (C6H9NO)n
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Structural Formula
Molecular Weight :  2500–3 000 000.
Description            : Povidone occurs as a fine, white to creamy-white colored, odourless
                                  or almost odourless.         
Typical Properties
Acidity/alkalinity
             pH : 3.0–7.0 (5% w/v aqueous solution).
Melting point       :  Softens at 150°C.
Moisture content
Povidone is very hygroscopic, significant amounts of moisture being absorbed at
low relative humidities. 
Solubility
Freely soluble in acids, chloroform, ethanol (95%), ketones, ethanol, and water;
practically insoluble in ether hydrocarbons, and mineral oil. In water, the concentration of
a solution is limited only by the viscosity of the resulting solution, Which is a function of
the K-value.
Viscosity (dynamic)
The viscosity of aqueous povidone solutions depends on both the concentration
and the molecular weight of the polymer employed. 
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Functional Category
Disintegrant; dissolution aid; suspending agent; tablet binder.
6.2.5 ETHYL CELLULOSE33
Nonproprietary Names
BP :   Ethylcellulose 
USP :  Ethyl cellulose
Synonyms : Aquacoat  ECD,  Aqualon,  Ashacel,  Ethocel,
ethylcellulosum.
Chemical name : 2-[4,5-diethoxy-2-(ethoxymethyl)-6-methoxyoxan-3-
yl]oxy-6-       (hydroxymethyl)-5-methoxyoxane-3,4-diol.
Empirical formula : C12H23O6(C12H22O5)n C12H23O5
Structural formula :
Functional Category: Coating agent,  flavoring agent,  tablet binder,  tablet  filler,
viscosity-increasing agent.
Description : A tasteless, free-flowing, white to light tan-colored powder.
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Typical properties
Density : (Bulk) 0.4 g/cm3
Melting Point : 165 to 185ºC
Glass transition
              Temperature: 129 to 133ºC
Specific gravity : 1.12 to 1.15 g/cm3
Hygroscopicity : It absorbs very little water from humid air or during immersion
Incompatibilities : With paraffin wax and microcrystalline wax material.
Solubility
Practically insoluble in glycerin,  propylene glycol,  and water.  Ethyl  cellulose that
contains  not  less than 46.5% of  ethoxyl  groups in  freely soluble in  chloroform,  95%
ethanol, ethyl acetate, methanol, and toluene.
Stability
Stable and slightly hygroscopic material. It  is chemically resistant to   alkalis both
dilute and concentrated and to salt solutions. It is more sensitive to acidic materials.
Storage condition
It should be stored at a temperature not exceeding 90ºF (32ºC) in a dry area.  Do
not store next to peroxides or other oxidizing agents.
Regulatory status
It is included in the FDA Inactive Ingredients Guide.
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Safety
It is a nontoxic, nonallergenic, and nonirritating material.   It is not metabolized,
therefore it is a noncaloric substance and not recommended for parenteral products.  It
may be an irritant to the eyes.
Application in pharmaceutical formulation technology
It is widely used in oral and topical pharmaceutical formulations. In tablets, it is
employed as a binder being blended dry or wet granulated.  It produces tablets with low
friability.
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5.3 EXCIPIENT PROFILE
5.3.1 LACTOSE34
Synonyms               : 4-(β-D-galactosido)-D-glucose, Lactochem, Microtose, milk sugar,
                                  saccharum lactis.
Chemical Name    and CAS Registry Number:
                     o-β-D-Galactopyranosyl-(1-›4)-α-D-glucopyranose anhydrous [63-42-3]
                    o- β-D-Galactopyranosyl-(1-›4)-α-D-glucopyranose monohydrate [64044-
51-5]
Empirical Formula     Molecular Weight
C12H22O11                     342.30 (anhydrous)
 C12H22O11.H2O            360.31 (monohydrate)
Structural Formula
Description              : White to off-white crystalline or powder. Lactose is odor-less and 
slightly                              sweet tasting. 
Typical Properties
Density                      : 1.540 for α-lactose monohydrate
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                                    1.589 for anhydrous β-lactose
Melting Point           : 201-202°C α-lactose monohydrate
                                    223°C for anhydrous α-lactose
                                    252.2°C for anhydrous β-lactose
 Moisture content   : Anhydrous lactose normally contains up to 1% w/w water.
Functional Category
 Tablet and capsule diluent.
Application
                     Lactose is widely used as a filler or diluent in tablets, capsules, and to a 
more limited extent in lyophilized products and infant feed formulas.other applications of
lactose as a carrier/diluent for inhalation products.
Stability and Storage Conditions
                         Under humid conditions (80% relative humididity and above) mold 
growth may occur. The purity of different lactoses can vary and colour evaluation may 
thus be important. The colour stability of various lactoses alsi differ.
Incompatibilities
                         A mailard type condensation reaction is likely to occur between lactose 
and compounds with a primary amine group to form brown coloured product. This 
reaction occurs more readily with the amorphous material rather than crystalline lactose.
Safety
        Lower doses  of lactose produce fewer adverse efffect, and lactose is better tolerated 
if taken with other food. As a result, there is a significant population with lactose 
malabsorption who can still ingest normal amount of lactose, such as that in milk, without
the development of significant adverse effects. 
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6. MATERIALS AND INSTRUMENTS
  6.1 Table 2: MATERIALS USED
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S.NO. MATERIALS GRADE
MANUFACTURES /
SUPPLIERS
1. Atorvastatin 
calcium
Pharma
Dr. Reddy’s Laboratories, Ltd, 
Hyderabad.
2. Carbopol 934 P Pharma
Loba Chemie Pvt. Ltd. Mumbai
3. HPMC K100M Pharma
Colorcon Asia Pvt. Ltd.
4.
Hydroxy ethyl 
cellulose Pharma
Loba Chemie Pvt. Ltd. Mumbai
5.
Ethyl cellulose
Pharma
SD Fine Chemicals Ltd.
6.
Polyvinylpyrolidon
e
Pharma Loba chemie pvt.ltd, Mumbai
7. Lactose A.R.
Loba Chemie Pvt. Ltd. Mumbai
6.2 Table 3: INSTRUMENTS USED
Sr.
No.
NAME OF INSTRUMENT MANUFACTURING COMPANY
1. Digital Balance Shimadzu ELB 300
2. Tablet hardness tester Monsanto tablet hardness tester.
3. Friability tester
Electrolab ET-2 friability test 
apparatus, India. 
4. Dissolution apparatus USP XXIII
Veego tablet dissolution apparatus, 
Chennai.
5.
Double beam UV 
Spectrophotometer
Perkin Elmer Lambda - 25 UV/VIS 
spectrometer
6. Tablet punching machine
Chamunda Pharma Machinery 
Pvt.Ltd, Ahmedabad
7. pH meter Hanna Instruments, Japan
8. FT-IR Spectrophotometer
Perkin Elmer spectrum RX1 FT-IR 
spectrometer.
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7. METHODOLOGY
7. Preformulation Studies:
It is one of the important prerequisite in development of any drug delivery system.
Preformulation studies were performed on the drug, which included compatibility studies.
A) Compatibility Studies35,36
One of the major requirement for the selection of suitable excipients or carrier for
pharmaceutical formulation is its compatibility.  Therefore in the present work a study
was carried out by using FTIR spectrometer to find out any possible chemical interaction
of atorvastatin calcium with carbopol 934P, HPMC K100M, Hydroxy ethyl cellulose and
Polyvinylpyrolidone.  Compatibility with excipients was confirmed by FTIR studies.
 Fourier transform infrared spectrometry (FTIR):
Compatibility  study  of  drug  with  the  excipient  was  determined  by  I.R.
Spectroscopy (FTIR) using Perkin Elmer spectrum RX1 FT-IR spectrometer model.  The
pellets were prepared at high compaction pressure by using KBr and the ratio of sample
to KBr is 1:100.  The pellets thus prepared were examined and the spectra of drug with
other ingredients in the formulations were compared with that of the original spectra.
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7.1  PREPARATION  OF  STANDARD  CALIBRATION  CURVE  OF
ATORVASTATIN CALCIUM37,38
Method:
Atorvastatin calcium can be estimated spectrophotometrically at 248 nm.
PREPARATION OF pH 6.8 BUFFER (PHOSPHATE BUFFER)
Dissolve 28.80 gms of disodium hydrogen phosphate and 11.45 gms of potassium
dihydrogen phosphate in sufficient water to produce 1000ml.
PREPARATION OF STANDARD SOLUTION FOR CALIBRATION CURVE
             10 mg Standard Atorvastatin calcium was accurately weighed and transferred to
100 ml volumetric  flask and was dissolved properly and diluted up to the mark with
methanol to produce a stock solution of  100 µg/ml.  Then 2.5ml of this solution was
diluted to 50ml with methanol. Appropriate amount of this stock solution were diluted
with the same solvent, yields concentrations of 5µg/ml, 10µg/ml, 15µg/ml 20µg/ml and
25µg/ml which were used for the construction ofcalibration curve.
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Table 4: STANDARD CURVE DATA FOR ATORVASTATIN CALCIUM
IN pH 6.8 PHOSPHATE BUFFER
S.No Concentration
In µg/ml 
Absorbance at
248 nm
1 5 0.145
2 10 0.286
3 15 0.436
4 20 0.568
5 25 0.692
The linear regression analysis was done on absorbance data points.
(Y = mx+c)
Where Y= Absorbance, m = slope, x = Concentration, c = Intercept.
Fig 4: STANDARD CURVE FOR ATORVASTATIN CALCIUM
IN pH 6.8 PHOSPHATE BUFFER
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7.2  PREPARATION  OF  MUCOADHESIVE  BUCCAL  TABLETS  OF
ATORVASTATIN CALCIUM
           Mucoadhesive buccal tablets containing atorvastatin calcium were prepared by
direct  compression method.  The  ingredients  of  the core  layer  (table:5)  were  weighed
accurately  and  mixed  by  trituration  in  a  glass  mortor  &  pestle.  The  mix  was  then
compressed using 8 mm die by a tablet press. In order to obtain constant tablets weight
the spray dried lactose was added as filler excipient in the core layer. After compression
of tablet the upper punch was removed carefully without disturbing the set up and mixed
ingredients of the backing layer were added over the tablet and compressed again.
Table 5: composition of mucoadhesive buccal tablets of atorvastatin calcium
Ingredients
       (mg)
Batch I Batch II Batch III
F1 F2 F3 F4 F5 F6 F7 F8 F9
ATR 10 10 10 10 10 10 10 10 10
Carbopol 934 20 20 20 25 25 25 30 30 30
HPMC
  K100M
15 20 25 15 20 25 15 20 25
HEC 15 10 5 15 10 5 15 10 5
PVP 30 6 6 6 6 6 6 6 6 6
Lactose
    (sd)
54 54 54 49 49 49 44 44 44
Backing layer 40 40 40 40 40 40 40 40 40
                                               
                                           Drug                  - Atorvastatin calcium
                        HPMC K100M - Hydroxy propyl methyl cellulose
         HEC                  - Hydroxy ethyl cellulose
                                           PVP                   - Polyvinylpyrolidone 30
                                           Backing Lay     : Ethyl cellulose
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7.3  PHYSICOCHEMICAL  EVALUATION  OF MUCOADHESIVE  BUCCAL
TABLETS 
I) Pre-Compression Parameters39
A) Angle of repose:
In  order  to  determine  the  flow  property,  the  Angle  of  repose  was
determined. It is the maximum angle that can be obtained between the free
standing surface of the powder heap and the horizontal plane.
                                                           = tan -1 (h/r)
          Where,   h = height, r = radius, θ = Angle of repose
Procedure:
5 grams of the sample was taken in a funnel fixed in a holder (6 cm) above the
surface at an appropriate height and a graph of sheet was placed below the funnel.  The
sample was passed through the funnel slowly.  The height of the powder heap formed was
measured. The circumference of the heap formed was drawn with a pencil on the graph
paper. The radius was measured and the angle of repose was determined using the above
formula. This was repeated five times for a sample.
 B) Determination of bulk density and tapped density
A quantity of 5g of the powder (W) from each formula was introduced into a 25 
ml measuring cylinder.   After the initial volume was observed, the cylinder was allowed 
to fall under its own weight onto a hard surface from the height of 2.5 cm at 2 sec 
intervals.   The tapping was continued until no further change in volume was noted.   The 
bulk density, and tapped density were calculated using the following formulas 
Bulk density = W / VO         and      Tapped density = W / Vf           
                             Where,     W = weight of the powder
                              VO = initial volume
                              Vf = final volume
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 C) Compressibility index (Carr’s indices):
Compressibility index is an important measure that can be obtained from the bulk
and tapped densities.   In theory, the less compressible a material the more flow able it is.
A material having values of less than 20 to 30% is defined as the free flowing material.
The limits are mentioned in the table no 6.
                          CI   = 100(VO – Vf)/V
Table No: 6
% Comp. Index Properties
5-12 Free flowing
12-18 Good
18-21 Fair
23-35 Poor
33-38 Very poor
>40 Extremely poor
D) Hauser’s Ratio:
It  indicates the flow properties of the powder and is measured by the ratio of
tapped density to the bulk density.
Hauser’s Ratio = (W / Vf) / (W / V0) where,
W / Vf = Tapped density      and     W / V0 = Bulk density. 
Thus,               
Hauser’s Ratio = Tapped density/Bulk density 
Table No: 7
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S. No. Hauser’s Ratio Property
1. 0-1.2 Free flowing
2. 1.2-1.6 Cohesive powder
II) Post-Compression Parameters34:
A) Shape of Tablets:
The compressed tablets were examined under the magnifying lens for the shape of
the tablet.
B) Tablet Dimensions: 
Thickness  and  diameter  were  measured  using  a  calibrated  dial  caliper.  Three
tablets  of  each  formulation  were  taken  randomly  and  thickness  was  measured
individually.
 C) Hardness: 
Hardness indicates the ability of a tablet to withstand mechanical shocks while
handling. The hardness of the tablets was determined using Monsanto hardness tester. It
is expressed in kg/cm2. Three tablets were randomly picked and hardness of the tablets
was determined.
D) Friability Test: 
The friability of tablets was determined using Roche friabilator. It is expressed in
percentage  (%).  Ten  tablets  were  initially  weighed  (w0 initial)  and  transferred  into
friabilator.  The  friabilator  was  operated  at  25rpm  for  4  minutes  or  run  up  to  100
revolutions. The tablets were weighed again (w).  The % friability was then calculated by 
                  Percentage of Friability = 100 (1-w0/w)
Percentage friability of tablets less than 1% is considered acceptable.
E) Weight Variation Test:
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Twenty tablets were selected at random and the average weight was determined.
Not more than two of the individual weights deviate from the average weight by more
than the percentage deviation shown in table and none deviates by more than twice the
percentage. USP official limits of percentage deviation of tablet are presented in the table
no : 8.
Table 8: Weight Variation Tolerances for Uncoated Tablets
S. No.
Average weight of Tablets
(mg)
Maximum percentage
difference allowed
1. 130 or Less 10
2. 130 to 324 7.5
3. More than 324 5.0
% Maximum positive deviation = (WH –A/ A) x 100
% Minimum negative deviation = (A-WL/ A) x 100
Where, WH = Highest weight in mg.
WL = Lowest weight in mg.
             A  = Average weight of tablet in mg
F. Drug Content Uniformity40
               5 Tablets were weighed, and an accurately weighed sample of powdered tablets
equivalent 10mg of ATR [equivalent to one tablet].  Quantity of powder equivalent to 10
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mg of  ATR was  weighed  and  dissolved in  60 ml  of  methanol  and  sonicated  for  10
minutes in a 100ml volumetric flask and this solution was filtered through Whatmann
No.1 filter paper. The residue was washed with 10ml methanol three times and volume
made upto 100ml with methanol. The solution obtained was diluted with the Methanol.
All  determinations  were  carried  out  in  three  replicates.  ATR  were  determined  by
measuring  the  absorbance  of  the  sample  at  246 nm.  Amount  of  drug  present  was
determined from the standard curve of atorvastatin calcium in methanol.
G. Mucoadhesion Strength41,42,43
Bio-adhesive strength of the tablets was measured on a modified physical balance.
The method used goat cheek pouch as the model mucosal membrane (a non keratinized
epithelium, comparable to human buccal mucosa) and pH 6.8 as the moistening fluid.
The two working of a double beam physical balance formed the basis of the bioadhesion
test  apparatus fabricated.  The right  pan was replaced with  chain setup with  adhesive
plate. The height of this total setup was adjusted to accommodate a glass container. This
setup was kept inside the glass container and the sides were balanced. The setup with
tablet was attached with mucosa in container, which was filled with isotonic phosphate
buffer (pH 6.8) kept at 37±1˚C.
The balance was kept  in this  position for 3  min and then slowly weights  are
increased on the right pan, till the tablet separated from the mucosal surface. The weight,
in gms, required to detach the tablets from the mucosal surface gave the measure of bio-
adhesive strength. Not more than 3 tablets were tested on each mucosal membrane. After
each measurement tissue washed with phosphate buffer (pH 6.8).
H. Swelling Index44, 45
46
The swelling properties and the erosion characteristics of tablets were evaluated
by determination of the percentage of hydration and matrix erosion or dissolution (DS).
The percent values were calculated according to the following equations:
Percentage  of   swelling  = (W2  −  W1) W2    *   100 
Each tablet was weighed (W1) and immersed in phosphate buffer at pH 6.8 for
predetermined times (1, 2,3,4,5,6,7,8,9,10,11,12 hours). After immersion, excess surface
water was removed from the tablets using filter paper and weighed (W2). The swollen
tablets were dried at 60°C for 24 hours in an oven and kept in a desiccator for 48 hours
prior to reweighing (W3). This experiment was performed in triplicate.
I. Measurement of Surface pH46, 47, 18
A combined glass electrode was used for this purpose. The buccal tablets were
kept in contact  with 0.5 ml of distilled water  for 1 h.  pH was noted by bringing the
electrode near the surface of the formulations and allowing it to equilibrate for 1 min. 
J. In Vitro Dissolution Studies48,49,50
   Dissolution parameters:
       Medium        : pH 6.8 phosphate buffer
      Apparatus     : USP - Type II (paddle)
       RPM             : 50
Temperature      : 37° ± 0.5° C
Medium volume: 500 ml
In  vitro  release studies:  The drug release rate from buccal  tablets  was studied
using the USP 28 type II dissolution test apparatus. To release the drug from one side the
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impermeable backing layer side of the tablet was fixed to a 2x2 cm glass slide with a
solution of cyanoacrylate adhesive. Then it was placed in the dissolution apparatus. The
dissolution medium was 500 mL of phosphate buffer pH 6.8. The release was performed
at 37±0.5°C, with a rotation speed of 50 rpm. Samples of 1ml were collected at different
time intervals up to 12 h and analyzed spectrophotometrically at 246 nm.
k. Ex vivo Buccal  Permeation  studies46
Porcine buccal  tissue from domestic goat  was obtained from a local  slaughter
house and used within 2 hours of slaughter. The tissue was stored in phosphate buffer pH
6.8 at 40 C after collection. The epithelium was separated from the underlying connective
tissue with a surgical technique and delipidized membrane was allowed to equilibrate for
approximately one hour in receptor buffer to regain lost elasticity.
Ex vivo permeation study of  atorvastatin buccal tablets  through the goat buccal
mucosa was performed using Franz-type diffusion cell. The freshly excised goat buccal
mucosal membrane was clamped between donor and receiver chambers of the Franz-type
diffusion  cell,  facing the  mucosal  side  towards  the  donor compartment.  The receiver
chamber was filled with fresh pH 6.8 buffer solution and after the buccal membrane was
equilibrated for 30 min. The buccal tablet was placed in donor chamber and the receptor
compartment was maintained at 37±0.20C and continuously stirred at 50 rpm throughout
the study.
Aliquots (1ml) were collected at predetermined time intervals and filtered through
a filter paper, and the amount of  drug  permeated through the buccal mucosa was then
determined by measuring the absorbance at 246 nm using a UV spectrophotometer. The
medium of the same volume (1ml), which was prewarmed at 37°C, was then replaced
into the receiver chamber. The experiments were performed in triplicate.
48
l.kinetics of drug release
In  order  to  understand  the  mechanism and  kinetics  of  drug  release,  the  drug
release data of the in vitro dissolution study were analyzed with various kinetics models
like  Zero  order,  first  order,  Higuchi ۥs  and  peppa ۥs.  Coefficient  of  correlation  was
calculated for the linear curves obtained by regression analysis.   
Fitting of Results into Different Kinetic Equations48 , 49: 
The  results  of  in-  vitro  and  ex  vivo  release  profile  obtained  for  all  the
formulations were plotted in modes of data treatment as follows: - 
1. Zero - order kinetic model - Cumulative % drug released Vs time.
2. First – order kinetic model - Log cumulative percent drug remaining Vs time.
3. Higuchi’s model - Cumulative percent drug released Vs square root of time.
4. Korsmeyer equation / Peppa’s model - Log cumulative percent drug released Vs
log time.
A) Zero order kinetics: 
Zero order release would be predicted by the following equation: -
At = A0 – K0t
Where,   At  = Drug release at time ‘t’.
  A0 = Initial drug concentration.
   K0 = Zero - order rate constant (hr-1).
When the data is plotted as cumulative percent drug release versus time, if the
plot is linear then the data obeys Zero – order equal to K0.
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B) First Order Kinetics:
First – order release would be predicted by the following equation:-
Log C = log C0 – Kt / 2.303
Where ,  C   = Amount of drug remained at time ‘t’.
   C0   = Initial amount of drug.
   K   = First – order rate constant (hr-1).
When the data is plotted as log cumulative percent drug remaining versus time
yields a straight line, indicating that the release follow first order kinetics.  The constant
‘K’ can be obtained by multiplying 2.303 with the slope values.
C) Higuchi’s model:
Drug release from the matrix devices by diffusion has been described by following
Higuchi’s classical diffusion equation: -
Q = [Dε / τ (2 A - εCs) Cst] ½
Where,
Q = Amount of drug released at time‘t’.
D = Diffusion coefficient of the drug in the matrix.
A = Total amount of drug in unit volume of matrix.
Cs = the solubility of the drug in the matrix.
ε = Porosity of the matrix.
τ = Tortuosity.
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t = Time (hrs) at which ‘q’ amount of drug is released.
Above equation may be simplified if one assumes that ‘D’, ‘Cs’ and ‘A’ are constant. 
Then equation becomes: -           
Q = Kt1/2
When the data is plotted according to equation i.e. cumulative drug release versus
square  root  of  time  yields  a  straight  line,  indicating  that  the  drug  was  released  by
diffusion mechanism. The slope is equal to ‘K’ (Higuchi’s 1963).
D) Korsmeyer equation / Peppa’s model: 
To study the mechanism of drug release from the sustained-release matrix tablets
of Ciprofloxacin, the release data were also fitted to the well-known exponential equation
(Korsmeyer equation/ Peppa’s law equation), which is often used to describe the drug
release behavior from polymeric systems.
Mt / Mα = Ktn          Where,
Mt / Mα = the fraction of drug released at time ‘t’.
K = Constant incorporating the structural and geometrical characteristics of      
        the drug / polymer system.
n = Diffusion exponent related to the mechanism of the release.
Above equation can be simplified by applying log on both sides,
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And we get: -
Log Mt / Mα = Log K + n Log t
When the data is plotted as log of drug released versus log time, yields a straight
line with a slope equal to ‘n’ and the ‘K’ can be obtained from y – intercept. For Fickian
release ‘n’ = 0.5 while for anomalous (non - Fickian) transport ‘n’ ranges between 0.5 and
1.0.
Table 9:  Mechanism of Drug Release as per Korsmeyer Equation / Peppa’s Model
S. No. n Value Drug release
1. 0.45 Fickian release
2. 0.45 < n <1.0 Non – Fickian release
3. 1.0 Class II transport
Curve Fitting of Release Profile:
                        The in- vitro dissolution data were fitted to the Korsmeyer and Peppa’s 
equation
Mt/M∞ = ktn
where Mt/M∞ represents the fraction of drug release at time t, k is the release rate
constant,  and  n  is  the  diffusion  coefficient.  The  entire  curve-fitting  analysis  was
performed  using  GraphPad  Prism  version  3.02  (GraphPad  Software,Inc)  and  Excel
(Microsoft) software. 
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9. RESULTS
In order to achieve the development of mucoadhesive buccal tablet dosage forms,
Atorvastatin  calcium  was  used  as  a  model  drug.  Mucoadhesive  buccal  tablets  were
formulated by direct compression method employing carbopol 934 P, HPMC K100M and
hydroxy ethyl cellulose in different ratios.
 In the present study nine formulations (F1-F9) were prepared by using carbopol
934 P, HPMC K100M and Hydroxy ethyl cellulose.  To know the mechanism of drug
release from these formulations, the data were fitted in various kinetic models like zero
order plot, first-order plot, Higuchi’s plot, and Korsmeyer equation / Peppa’s model et
al’s equations. 
The results related to physicochemical, in- vitro evaluation and ex-vivo evaluation
of mucoadhesive buccal tablets of atorvastatin calcium are given in Table: 15 – 28.
8.1 Preformulation Studies (Compatibility Studies):
Compatibility studies were performed by using FT-IR spectrophotometer.  The IR
Spectrum of pure me Atorvastatin Calcium drug was compared with the IR spectrum of
physical  mixture  of  Atorvastatin  Calcium  with  Carbopol,  Hydroxy  propyl  methyl
cellulose K100M, Hydroxy ethyl cellulose, PVP  and other excipients.
There was no appearance or disappearance of any characteristics peaks related to
the drug.  This  shows  that  there is  no chemical  interaction between  the  drug and the
polymers.   
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2.2 EVALUATION OF BLEND CHARACTERISTICS OF ATORVASTATIN 
CALCIUM
I) Pre-compression parameters:
The powder blends of different formulation were evaluated for angle of repose,
loose  bulk  density  (LBD),  tapped  bulk  density  (TBD),  compressibility  index,  and
Hauser’s ratio.  The results of these evaluations are as follows: -
a)  Angle of Repose (θ):
The angle of repose for the formulated blend was carried out and the results were
shown in the table.  It concludes the entire formulation blend was found to be in the range
310 45' ±0.1210 to 340 02' ±0.4347.  The values are in Table No: 10.
b) Bulk Density:
Bulk density is  used for  the measurement of  Compressibility index.  The bulk
density ranged from 0.431±0.0005 to 0.343±0.0080 respectively. The values are in Table
No: 11.
c) Tapped Density:
Tapped density is used for the measurement of Compressibility index. The tapped 
density ranged from 0.506±0.506 to 0.425±0.0066 respectively. The values are in Table 
No: 12.
d) Compressibility Index: - 
Compressibility  index  was  carried  out,  it  is  found  between  19.280±1.201  to
13.760±1.021. The values are mentioned in Table: 13.
e) Hauser’s Ratio:
The Hauser’ ratio ranged from 1.238 ± 1.018 to 1.159± 0.013. The values are
mentioned in Table: 14.
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Table 10: Physical Characteristics of Atorvastatin calcium  Powder Blend
F.Cod
e
Angle of
repose(°
)
Mean ±
S.D
Bulk
density
(gm/cc)
Mean±S.
D
Tapped
density
(gm/cc)
Mean±S.
D
Compressibilit
y Index
Mean ± S.D
Hausner’s
Ratio
Mean±S.
D
F1
32˚05
' ± 0.428
0.388
± 0.0081
0.45
± 0.0041
14.707
± 0.482
1.172
± 0.006
F2
32˚26'
± 0.189
0.386
± 0.0052
0.459
± 0.0015
14.803
± 0.935
1.173 ±
0.012
F3
34˚
 ± 0.392
0.373
± 0.0016
0.437
± 0.0126
13.760
± 1.021
1.159
± 0.013
F4
33˚18'
±0.0802
0.431
± 0.0005
0.506
± 0.506
14.797
± 0.855
1.173
± 0.015
F5
33˚01'
± 0.459
0.386
± 0.0070
0.473
± 0.0037
18.511
± 0.865
1.226
± 0.012
F6
32˚06'
± 0.551
0.415
± 0.0050
0.496
± 0.0050
16.529
± 0.1222
1.198
± 0.017
F7
34˚02'
 ± 0.434
0.362 
± 0.0017
0.440
± 0.0218
18.318
± 0.789
1.215
± 0.015
F8
31˚45'
 ± 0.121
0.413
± 0.0026
0.501
± 0.0030
17.671
± 0.848
1.214
± 0.012
F9
32˚39'
 ± 0.190
0.343
± 0.0080
0.425
± 0.0066
19.280
± 1.201
1.238
± 0.018
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8.3 Physical evaluation parameter of mucoadhesive buccal tablets of Atorvastatin 
calcium
Atorvastatin  calcium  mucoadhesive  buccal  tablets  were  evaluated  for  various
physical parameters – Hardness, thickness, Friability, Weight variation, diameter etc.
8.3.1 Thickness: 
The thickness of all batches ranged from 3.49±0.005 to 3.21±0.010 mm as shown
in the Table -16.
8.3.2 Diameter:
The diameter of all batches ranged from 3.49±0.005 to 3.21±0.010 mm as shown
in the Table -16.
8.3.3 Hardness Test:
The hardness of all batches ranged from 5.1 to 5.6 kg/cm2  as shown in the Table
-15. 
8.3.4 Friability Test:
The percentage friability of all batches ranged from 0.361 % to 0.464 % as shown
in the Table-17.           
8.3.5 Weight Variation Test:
The  percentage  weight  variations  for  all  formulations  are  performed.  All  the
formulations (F1-F9) passed weight variation test as per the Pharmacopoeias limits of 5%
as shown in the Table -18.
8.3.6 Drug content uniformity:
Drug content was found to be ranged from 99.01±0.56 to 96.95±0.20 as shown in
the Table -19
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TABLE 11: POST COMPRESSION PARAMETERS
F
Code
Thickness
(mm)±SD
Diameter
(mm)±SD
Hardness
(Kg/cm2)±
SD
Friability
(%)±SD
Weight
variation
(mg) ±SD
% drug
content
F1 3.35±
0.011
8.14 ±
0.032 5.2±0.115
0.464
±0.004
159.7
±0.493
98.87
±0.38
F2 3.31±
0.005
8.91 ±
0.109 5.3±0.057
0.413
±0.002
158.9
±0.251
99.01
±0.56
F3 3.40±0.00
5
8.19 ±
0.122 5.6±0.152
0.398
±0.002
159.1
±0.700
96.95
±0.20
F4 3.39±
0.005
8.69 ±
0.124 5.6±0.115
0.394
±0.004
158.9
±0.519
97.38
±0.84
F5 3.49±
0.005
8.24 ±
0.121 5.3±0.115
0.418
±0.004
158.5
±0.602
97.38
±0.65
F6 3.27±
0.015
8.66 ±
0.071 5.5±1.157
0.392
±0.002
158.7
±0.472
98.26
±0.29
F7 3.41±
0.011
8.82 ±
0.233 5.1±0.115
0.405
±0.003
158.4
±0.493
97.54
±0.98
F8 3.21±
0.010
8.96 ±
0.058 5.1±0.100
0.361
±0.003
158.7
±0.435
98.62
±0.52
F9 3.33±
0.015
8.56 ±
0.088 5.4±0.100
0.408
±0.003
158.9
±0.602
97.86
±0.17
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8.3.7 Swelling study
 Swelling studies were conducted for all formulations and the results were shown
in table all the formulations were hydrated generally by keeping the tablets in contact
with water for 1hour to 12hours.
Table 12: swelling index profile of formulations
Time
hr
F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
1 0.21 0.26 0.16 0.21 0.27 0.18 0.10 0.22 0.32
2 0.42 0.66 0.48 0.34 0.41 0.35 0.29 0.54 0.63
3 0.84 0.91 0.92 0.56 0.55 0.61 0.56 0.76 0.99
4 1.10 1.01 1.45 0.75 0.88 0.96 0.81 1.08 1.21
5 1.46 1.57 1.73 1.17 1.21 1.45 0.95 1.33 1.46
6 1.95 1.88 1.98 1.38 1.51 1.88 1.14 1.56 1.75
7 2.11 2.22 2.16 1.63 1.90 2.11 1.35 1.98 1.90
8 2.25 2.35 2.31 2.08 2.20 2.38 1.58 2.18 2.06
9 2.35 2.42 2.48 2.32 2.49 2.51 2.01 2.27 2.22
10 2.41 2.46 2.56 2.49 2.55 2.58 2.20 2.36 2.48
11 2.43 2.51 2.61 2.52 2.59 2.63 2.31 2.44 2.56
12 2.48 2.55 2.64 2.54 2.62 2.68 2.38 2.47 2.67
Fig 5: Swelling index Vs Time [F1-F3]
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Fig 6 :Swelling index Vs Time [F4-F6]
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Figure 7: Swelling index Vs Time [F7-F9]
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Fig 8: swelling index comparison
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Fig 9: swelling index comparison at 4 hour, 8 hour and 12 hour
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8.3.8 Ex vivo Mucoadhesive Strength:
Mucoadhesion studies were carried out by Ex vivo method using freshly obtained
goat buccal mucosa without any further treatment. The property of polymer is closely
associated  with  mucoadhesion  because  polymer  swelling  depended  upon  the  water
inhibition which in turn increases the diffusion and interpenetration of macromolecules.
Increasing the total polymer content of formulation induces more adhesion strength. The
possible explanation for such behavior is  due to high concentration of carpobol upon
exposure to the moist surfaces, the pH of the microenvironment became acidic which
caused increases in mucoadhesion.  
Table 13: Mucoadhesive strength
S.NO FORMULATIONS TRIALI
TRIAL
II
TRIAL
III MEAN ± SD
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1 F1 9.9 8.9 9.6 9.4±0.51
2 F2 10.9 10.5 11.6 11.03±0.61
3 F3 11.8 12.4 10.5 11.50±0.97
4 F4 13.2 12.8 12.4 12.8±0.40
5 F5 14.8 14.1 14.5 14.46±0.35
6 F6 15.2 16.1 15.7 15.03±0.25
7 F7 15.8 16.3 16.2 16.1±0.26
8 F8 17.9 19.0 18.7 18.53±0.56
9 F9 20.1 18.9 19.6 19.53±0.60
Fig 10: comparison of mucoadhesive strength
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9.3.9 Measurement of surface pH
The  microenvironment  pH  of  the  buccal  tablets  was  determined  in  order  to
investigate the possibility any side effect in vivo. The another studies demonstrated that a
low  surface  PH  caused  damage  to  a  contacting  mucosal  surface.  Therefore,  it  was
important in the present study to determine if any extreme surface pH changes occurred
with the mucoadhesive buccal tablet development.
Table 14: Measurement of surface pH
S.NO FORMULATIONS TRIALI
TRIAL
II
TRIAL
III MEAN SD 
1 F1 6.8 6.4 6.5 6.5 0.208
`2 F2 7.2 7.1 7.0 7.1 0.100
68
3 F3 7.1 6.9 7.1 7.0 0.115
4 F4 7.0 7.1 7.1 7.0 0.057
5 F5 6.7 6.8 6.9 6.8 0.100
6 F6 6.9 7.0 6.8 6.9 0.100
7 F7 7.2 7.0 7.2 7.1 0.115
8 F8 6.6 6.8 6.6 6.6 0.115
9 F9 6.9 6.7 6.6 6.7 0.152
8.3.10 IN VITRO DRUG RELEASE PROFILE
Release of atorvastatin calcium from the buccal tablets was studied in phosphate
buffer pH 6.8 (500 ml) in USP XXIV employing apparatus II. One tablet containing 10
mg of atorvastatin calcium, at paddle speed of 50 rpm and a temperature of 37 ± 0.5°C
were employed in each test. Samples were withdrawn through a filter (0.45µ) at different
time intervals, suitably diluted and assayed spectrophotometrically at 246 nm using a UV
double  beam  spectrophotometer  and  drug  release  compared  with  various  polymer
concentrations. Drug release experiments were conducted in triplicates.
In vitro drug release data of all formulations of atorvastatin calcium was subjected
to curve fitting analysis according to zero order,  first  order kinetics and according to
Higuchi´s and peppa´s models to ascertain mechanism of drug release.
`
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Table No : 15
70
Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 17.501 16.852 17.998 17.450±0.574
2 22.484 21.773 21.134 21.797±0.675
3 28.482 28.528 28.794 28.601±0.168
4 35.854 35.652 34.382 35.296±0.798
5 47.936 47.192 46.094 47.074±0.926
6 52.252 52.984 52.189 52.140±0.905
7 57.124 58.232 57.324 57.560±0.590
8 65.688 66.422 66.121 66.077±0.364
9 71.857 70.138 72.212 71.402±1.109
10 78.394 78.644 79.524 78.854±0.593
11 87.346 88.124 87.194 87.554±0.498
12 96.023 95.792 95.184 95.666±0.433
IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F2
Table no: 16
71
IN
VITRO DRUG RELEASE PROFILE FOR FORMULATION F3
Table no: 17
72
Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 15.962 14.681 14.128 14.923±0.940
2 21.884 21.324 21.184 21.464±0.894
3 27.885 26.185 25.554 26.874±0.894
4 32.258 33.184 32.192 32.544±0.554
5 39.089 38.467 38.186 38.580±0.462
6 46.184 47.512 47.782 47.159±0.855
7 55.618 56.915 55.271 55.934±0.866
8 62.194 63.886 62.727 62.935±0.865
9 73.857 74.135 73.293 85.830±0.659
10 86.510 85.192 85.790 85.830±0.659
11 91.145 90.817 91.497 91.153±0.340
12 96.614 96.401 97.124 96.124±96.713
IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F4
Table no: 18
73
Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 15.962 14.321 15.618 15.300±0.865
2 21.384 21.861 22.424 21.889±0.520
3 27.881 27.184 28.713 27.926±0.765
4 39.194 38.572 39.783 39.183±0.605
5 46.929 47.184 46.692 46.935±0.246
6 58.127 57.189 57.742 57.684±0.474
7 62.685 62.138 63.716 62.846±0.801
8 67.184 68.125 68.915 68.074±0.866
9 73.857 72.447 73.124 73.142±0.705
10 79.544 80.192 79.722 79.819±0.348
11 87.195 86.334 86.192 86.573±0.542
12 93.915 94.752 94.138 94.268±0.433
IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F5
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Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 18.982 17.109 17.714 17.935±0.955
2 23.114 22.182 23.816 23.816±0.819
3 27.584 26.182 26.789 26.851±0.703
4 34.716 33.189 33.430 33.855±0.745
5 39.089 38.419 38.416 38.641±0.387
6 43.815 44.515 43.023 43.784±0.746
7 52.693 51.312 50.122 51.375±1.287
8 65.109 65.324 64.017 64.816±0.700
9 71.857 70.168 69.832 70.619±1.085
10 76.394 77.681 76.891 76.988±0.649
11 88.346 87.638 88.431 88.138±0.435
12 95.618 94.329 96.134 95.360±0.929
Table no :19
IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F6
Table no: 20
75
Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 13.142 12.816 13.134 13.030±0.185
2 21.713 21.424 22.318 21.818±0.456
3 30.328 31.682 29.131 30.380±1.276
4 37.178 36.124 36.816 36.706±0.534
5 44.719 46.128 44.115 44.987±1.037
6 55.888 54.798 55.323 55.336±0.545
7 64.382 63.787 64.813 64.327±0.515
8 70.294 71.792 70.531 70.872±0.805
9 78.818 77.137 78.198 78.051±0.850
10 84.315 83.124 84.915 84.118±0.911
11 90.198 91.713 901.770 90.893±0.765
12 97.467 96.185 97.074 96.908±0.656
IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F7
Table no: 21
76
Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 22.348 21.889 21.033 21.756±0.667
2 30.176 29.701 29.215 29.697±0.480
3 35.219 34.138 35.713 35.023±0.805
4 40.184 39.632 39.141 39.652±0.521
5 44.515 44.815 43.134 44.154±0.896
6 47.817 48.127 47.124 47.713±0.473
7 57.693 58.613 59.543 58.616±0.925
8 69.715 68.185 69.008 68.969±0.765
9 76.138 75.714 75.983 75.945±0.214
10 83.650 84.365 83.218 83.744±0.579
11 90.127 91.423 89.809 90.453±0.855
12 96.532 96.654 95.340 96.175±0.726
IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F8
Table no: 22
77
Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 15.962 14.192 14.038 14.730±1.069
2 20.384 21.483 21.943 21.270±0.801
3 27.135 26.836 27.153 27.641±0.178
4 34.638 34.618 35.138 34.338±0.970
5 38.517 39.843 37.058 38.472±1.393
6 47.428 48.368 47.059 47.618±0.674
7 61.134 60.688 61.853 61.225±0.587
8 67.641 67.098 66.138 66.957±0.763
9 73.857 72.746 71.162 72.588±1.354
10 79.115 80.713 78.506 79.444±1.400
11 87.635 86.583 87.192 87.136±0.728
12 93.128 94.138 94.986 94.084±0.930
IN VITRO DRUG RELEASE PROFILE FOR FORMULATION F9
Table no: 23
78
Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 11.859 12.698 13.456 12.671±0.798
2 16.334 17.186 16.168 16.562±0.546
3 24.866 23.186 23.916 23.989±0.842
4 31.218 33.168 33.612 32.666±1.274
5 37.127 38.128 37.716 37.657±0.503
6 45.718 46.186 46.913 46.272±0.602
7 53.694 54.713 531.198 53.868±0.772
8 68.899 67.816 68.784 68.499±0.594
9 68.384 67.136 68.731 68.083±0.838
10 77.463 78.802 76.314 77.526±1.245
11 86.145 86.912 86.716 86.591±0.398
12 95.541 96.128 96.932 96.200±0.698
CUMULATIVE PERCENTAGE DRUG RELEASE 
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Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 14.584 14.139 15.720 14.814±0.815
2 21.658 20.716 22.189 21.530±0.758
3 27.343 26.716 26.217 26.758±0.564
4 34.832 33.192 34.917 34.313±0.972
5 39.465 40.128 41.762 40.451±1.182
6 47.763 48.716 47.185 47.888±0.773
7 56.078 55.862 56.632 56.190±0.397
8 65.957 65.444 64.504 65.301±0.736
9 73.562 74.710 75.313 74.528±0.887
10 82.809 83.404 81.312 82.508±1.078
11 92.811 90.113 92.213 91.712±1.417
12 98.645 97.632 96.503 97.593±1.072
Fig 11: comparative release profile of formulations F1 – F9
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8.4  Kinetic values obtained from different plots of Formulations (F1– F9)
Table No: 24
80
F.code
Zero-order
plots
First-order
plots
Higuchi’s
Plots
Korsmeyer et al’s
plots
Possible
Drug
Release
mechanism
Regression
Coefficient
(R2)
Regression
Coefficient
(R2)
Regression
coefficient
(R2)
Slope
(n)
Regressio
n
coefficient
(R2)
F1 0.990 0.847 0.968 0.856 0.991 Zero orderFickian
F2 0.992 0.842 0.945 1.041 0.994 Zero order
Fickian
F3 0.987 0.902 0.985 10.768 0.992
Zero order
Fickian
F4 0.985 0.817 0.928 0.991 0.984 Zero order
Fickian
F5 0.994 0.867 0.986 0.855 0.996 Zero orderNon-fickian
F6 0.979 0.848 0.943 0.871 0.980 Zero orderNon-fickian
F7 0.995 0.889 0.972 0.992 0.995 Zero orderNon-fickian
F8 0.996 0.798 0.956 0.998 0.995 Zero orderNon-fickian
F9 0.997 0.812 0.964 0.957 0.996 Zero order
non-fickian
In vitro Dissolution Profile and Kinetic Plots of Formulation (F1)
Fig 12:  Zero order Kinetic Plots of Formulation 
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Fig 13: First order Kinetic Plots of Formulation 
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Fig 14: Korsmeyer Kinetic Plots of Formulation
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Fig 15: Higuichi’s Kinetic Plots of Formulation
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In vitro Dissolution Profile and Kinetic Plots of Formulation (F2)
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Fig 16: Zero order Kinetic Plots of Formulation
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Fig 17: First order Kinetic Plots of Formulation
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Fig 18: Korsmeyer Kinetic Plots of Formulation
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Fig 19: Higuichi’s Kinetic Plots of Formulation 
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In vitro Dissolution Profile and Kinetic Plots of Formulation (F3)
Fig 20: Zero order Kinetic Plots of Formulation
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Fig 21s: First order Kinetic Plots of Formulation
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Fig 22: Korsmeyer Kinetic Plots of Formulation
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Fig 23: Higuichi’s Kinetic Plots of Formulation
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In vitro Dissolution Profile and Kinetic Plots of Formulation (F4)
Fig 24: Zero order Kinetic Plots of Formulation
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Fig 25: First order Kinetic Plots of Formulation
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Fig 26: Korsmeyer Kinetic Plots of Formulation
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Fig 27: Higuichi’s Kinetic Plots of Formulation
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In vitro Dissolution Profile and Kinetic Plots of Formulation (F5)
Fig 28: Zero order Kinetic Plots of Formulation
0 2 4 6 8 10 12 14
0
20
40
60
80
100
120
R² = 0.99
Zero order plot
time(hrs)
%
 
dr
ug
 
re
le
as
e
90
Fig 29: First order Kinetic Plots of Formulation
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Fig 30: Korsmeyer Kinetic Plots of Formulation
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Fig 31: Higuichi’s Kinetic Plots of Formulation
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In vitro Dissolution Profile and Kinetic Plots of Formulation (F6)
Fig 32: Zero order Kinetic Plots of Formulation
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Fig 33: First order Kinetic Plots of Formulation
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Fig 34: Korsmeyer Kinetic Plots of Formulation
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Fig 35: Higuichi’s Kinetic Plots of Formulation
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In vitro Dissolution Profile and Kinetic Plots of Formulation (F7)
Fig 36: Zero order Kinetic Plots of Formulation
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Fig 37: First order Kinetic Plots of Formulation
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Fig 38: Korsmeyer Kinetic Plots of Formulation
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Fig 39: Higuichi’s Kinetic Plots of Formulation
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In vitro Dissolution Profile and Kinetic Plots of Formulation (F8)
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Fig 40: Zero order Kinetic Plots of Formulation
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Fig 41: First order Kinetic Plots of Formulation
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Fig 42: Korsmeyer Kinetic Plots of Formulation
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Fig 43: Higuichi’s Kinetic Plots of Formulation
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In vitro Dissolution Profile and Kinetic Plots of Formulation (F9)
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Fig 44: Zero order Kinetic Plots of Formulation
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Fig 45: First order Kinetic Plots of Formulation
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Fig 46: Korsmeyer Kinetic Plots of Formulation
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Fig 47: Higuichi’s Kinetic Plots of Formulation
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8.6 EX VIVO DRUG PERMEATION FOR FORMULATION
All the nine formulations of prepared mucoadhesive buccal tablets of atorvastatin
calcium were subjected to ex vivo permeation studies were carried out by using Franz
diffusion cell. The values were tabulated in the following tables.                   
EX VIVO DRUG PERMEATION FOR FORMULATION F1
Table no 24
                                                    
101
Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 2.954 3.110 2.990 3.017±0.0828
2 7.354 7.575 7.781 7.570±0.213
3 12.210 11.803 12.121 12.044±0.214
4 19.321 19.991 19.500 19.604±0.346
5 26.718 26.937 27.101 26.918±0.192
6 34.890 34.751 34.230 34.623±0.347
7 42.387 42.110 41.989 42.162±0.204
8 45.988 44.113 44.221 44.107±0.116
9 51.816 51.550 51.982 51.782±0.217
10 59.210 58.991 58.880 59.027±0.167
11 67.586 67.238 67.690 67.504±0.236
12 75.801 75.210 75.394 75.468±0.302
                     
EX VIVO PERMEATION FOR FORMULATION F2
Table no 25
102
Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 7.982 7.310 8.104 7.798±0.427
2 12.298 12.353 11.991 12.214±0.195
3 16.898 17.121 16.985 16.991±0.115
4 22.817 22.534 22.237 22.529±0.290
5 28.976 29.219 28.898 29.128±0.334
6 35.821 35.690 36.100 35.870±0.209
7 43.894 43.234 43.983 43.703±0.409
8 51.970 52.210 52.319 52.166±0.178
9 60.129 60.713 59.897 60.246±0.420
10 67.810 67.343 68.137 67.763±0.399
11 72.584 72.373 72.981 72.312±0.306
12 77.991 77.404 77.151 77.848±0.393
                          
                         
EX VIVO DRUG PERMEATION FOR FORMULATION F3
                                                                   Table no 26
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Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 7.389 6.890 6.690 6.989±0.360
2 11.121 11.314 10.881 11.105±0.216
3 17.890 18.134 17.534 17.852±0.301
4 23.210 23.811 22.901 23.307±0.462
5 30.568 31.217 30.896 30.893±0.324
6 35.996 36.324 36.585 36.301±0.295
7 42.312 41.889 42.529 42.243±0.325
8 51.812 52.234 51.594 51.880±0.325
9 58.816 59.213 59.325 59.051±0.208
10 67.713 68.211 67.934 67.952±0.249
11 76.312 76.690 75.861 76.287±0.415
12 84.410 85.128 84.816 84.784±0.360
BATCH II
                         EX VIVO DRUG PERMEATION FOR FORMULATION F4
Table no 27
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Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 10.221 9.850 10.214 10.095±0.212
2 14.213 13.710 14.580 14.127±0.436
3 18.410 18.213 19.381 18.668±0.625
4 23.160 23.675 22.750 23.197±0.460
5 31.890 31.217 32.318 31.808±0.555
6 37.515 38.308 37.121 37.648±0.604
7 43.897 44.412 43.785 44.031±0.334
8 53.116 53.855 52.779 53.250±0.550
9 60.413 60.890 61.412 60.905±0.499
10 69.235 69.990 68.185 69.136±0.906
11 77.121 76.667 77.685 77.157±0.510
12 86.584 85.764 86.125 86.157±0.411
BATCH II
                         EX VIVO DRUG PERMEATION FOR FORMULATION F5
                                                                   Table no 28
                                                      
BATCH II
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Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 6.985 5.997 6.385 6.455±0.497
2 10.584 11.313 10.213 10.703±0.559
3 16.813 16.213 17.318 16.781±0.553
4 23.185 23.681 22.891 23.254±0.402
5 29.135 28.890 29.524 29.183±0.319
6 36.813 37.185 35.994 36.664±0.609
7 44.185 44.767 44.585 45.179±0.591
8 53.125 53.885 52.482 53.164±0.702
9 58.361 58.817 59.212 58.796±0.425
10 68.861 68.217 67.719 68.265±0.572
11 77.121 77.818 76.836 77.258±0.505
12 84.589 85.301 84.761 83.883±0.371
EX VIVO DRUG PERMEATION FOR FORMULATION F6
Table no 29
BATCH III
                         EX VIVO DRUG PERMEATION FOR FORMULATION F7
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Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 4.954 4.321 5.224 4.833±0.463
2 9.876 9.420 8.886 9.394±0.495
3 16.803 15.986 16.349 16.379±0.409
4 22.845 23.185 23.585 23.205±0.370
5 30.312 30.916 31.181 30.803±0.445
6 36.618 37.321 36.513 36.513±0.439
7 43.976 42.524 43.124 43.208±0.729
8 49.432 49.916 50.525 49.957±0.547
9 55.581 56.918 55.997 56.165±0.684
10 66.301 66.716 66.519 67.178±0.607
11 74.481 74.892 73.756 74.76±0.575
12 83.321 83.990 82.627 83.312±0.681
                                                                   Table no 30
                         EX VIVO DRUG PERMEATION FOR FORMULATION F8
                                                                   Table no 31
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Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 5.320 5.918 5.133 5.457±0.409
2 10.231 11.432 10.872 10.845±0.601
3 17.868 18.324 18.525 18.172±0.331
4 23.485 24.915 24.215 24.205±0.715
5 31.586 30.315 30.915 30.938±0.635
6 37.425 37.608 37.918 37.650±0.249
7 42.781 43.623 43.925 43.443±0.592
8 52.325 51.353 51.915 51.197±0.788
9 59.723 60.399 59.232 59.784±0.585
10 67.896 68.282 67.434 67.870±0.424
11 77.383 77.913 76.219 77.171±0.866
12 84.404 85.905 86.672 85.993±0.800
                         EX VIVO DRUG PERMEATION FOR FORMULATION F9
                                                                   Table no 32
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Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 2.958 3.816 2.125 2.966±0.845
2 8.147 8.581 7.769 8.165±0.406
3 13.983 14.481 14.394 14.286±0.266
4 20.618 21.327 20.882 20.942±0.358
5 28.121 28.890 27.425 28.145±0.732
6 35.381 36.613 35.525 35.839±0.673
7 42.761 43.481 42.863 43.035±0.389
8 50.301 51.311 50.863 50.825±0.506
9 57.289 58.115 57.896 57.766±0.427
10 65.815 66.537 65.389 65.913±0.580
11 75.904 75.224 74.898 74.008±0.842
12 84.543 83.325 84.743 84.203±0.767
Fig 48:
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Time
(hrs)
Cumulative % of
Drug Release Mean ±SD
1 2 3
0 0 0 0 0
1 9.701 8.632 9.215 9.182±0.535
2 13.850 14.115 13.382 13.782±0.371
3 16.421 16.885 17.471 16.916±0.527
4 22.310 23.440 22.798 22.839±0.568
5 30.706 31.412 31.116 31.078±0.354
6 36.930 35.622 36.512 36.354±0.668
7 42.432 43.527 42.815 42.924±0.555
8 49.552 50.244 49.146 49.647±0.555
9 57.681 58.486 58.919 58.361±0.626
10 68.343 69.432 68.717 68.830±0.553
11 78.935 77.116 78.629 78.226±0.974
12 91.936 92.892 92.425 92.417±0.478
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8.5 Kinetic values obtained from different plots of Formulations (F1– F9)
Table - 33
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F.code
Zero-order
plots
First-order
plots
Higuchi’s
Plots
Korsmeyer et al’s
plots
Possible
Drug
Release
mechanism
Regression
Coefficient
(R2)
Regression
Coefficient
(R2)
Regression
coefficient
(R2)
Slope
(n)
Regressio
n
coefficient
(R2)
F1 0.988 0.890 0.946 1.339 0.999 Zero orderFickian
F2 0.990 0.894 0.938 1.225 0.999 Zero order
Fickian
F3 0.992 0.896 0.945 1.172 0.997 Zero orderFickian
F4 0.991 0.890 0.936 1.174 0.996 Zero order
Fickian
F5 0.993 0.901 0.949 1.194 0.998 Zero orderNon-fickian
F6 0.994 0.909 0.957 1.151 0.998 Zero orderNon-fickian
F7 0.995 0.908 0.956 1.141 0.998 Zero orderNon-fickian
F8 0.993 0.909 0.958 1.239 0.999 Zero orderNon-fickian
F9 0.985 0.859 0.923 1.200 0.994 Zero order
non-fickian
Ex vivo release Profile and Kinetic Plots of Formulation (F1)
Fig 49: Zero order Kinetic Plots of Formulation 
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Fig 50: First order Kinetic Plots of Formulation 
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Fig 51: Korsmeyer Kinetic Plots of Formulation
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Fig 52: Higuichi’s Kinetic Plots of Formulation
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Ex vivo release Profile and Kinetic Plots of Formulation (F2)
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Fig 53: Zero order Kinetic Plots of Formulation 
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Fig 54: First order Kinetic Plots of Formulation 
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Fig 55: Korsmeyer Kinetic Plots of Formulation
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Fig 56: Higuichi’s Kinetic Plots of Formulation
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Ex vivo release Profile and Kinetic Plots of Formulation (F3)
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Fig 57: Zero order Kinetic Plots of Formulation 
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Fig 58: First order Kinetic Plots of Formulation
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Fig 59: Korsmeyer Kinetic Plots of Formulation
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Fig 60: Higuichi’s Kinetic Plots of Formulation
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Ex vivo release Profile and Kinetic Plots of Formulation (F4)
Fig 61: Zero order Kinetic Plots of Formulation
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Fig 62: First order Kinetic Plots of Formulation
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Fig 63: Korsmeyer Kinetic Plots of Formulation
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Fig 64: Higuichi’s Kinetic Plots of Formulation
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Ex vivo release Profile and Kinetic Plots of Formulation (F5)
Fig 65: Zero order Kinetic Plots of Formulation
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Fig 66: First order Kinetic Plots of Formulation
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Fig 67: Korsmeyer Kinetic Plots of Formulation
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Fig 68: Higuichi’s Kinetic Plots of Formulation
121
0.5 1 1.5 2 2.5 3 3.5 4
0
20
40
60
80
100
R² = 0.95
Higuchi plot
Square root time
%
 
dr
ug
 
re
lea
se
Ex vivo release Profile and Kinetic Plots of Formulation (F6)
 
Fig 69: Zero order Kinetic Plots of Formulation 
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Fig 70: First order Kinetic Plots of Formulation
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Fig 71: Korsmeyer Kinetic Plots of Formulation
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Fig 72: Higuichi’s Kinetic Plots of Formulation
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Ex vivo release Profile and Kinetic Plots of Formulation (F7)
Fig 73: Zero order Kinetic Plots of Formulation
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Fig 74: First order Kinetic Plots of Formulation
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Fig 75: Korsmeyer Kinetic Plots of Formulation
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Fig 76: Higuichi’s Kinetic Plots of Formulation
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Ex vivo release Profile and Kinetic Plots of Formulation (F8)
Fig 77: Zero order Kinetic Plots of Formulation
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Fig 78: First order Kinetic Plots of Formulation
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Fig 79: Korsmeyer Kinetic Plots of Formulation
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Fig 80: Higuichi’s Kinetic Plots of Formulation
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Ex vivo release Profile and Kinetic Plots of Formulation (F9)
Fig 81: Zero order Kinetic Plots of Formulation 
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Fig 82: First order Kinetic Plots of Formulation
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Fig 83: Korsmeyer Kinetic Plots of Formulation
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Fig 84: Higuichi’s Kinetic Plots of Formulation
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9. DISCUSSION
In the present work efforts have been made to develop mucoadhesive properties
of buccal tablet using direct compression technique involving mucoadhesive polymers
like carbopol 934P, various cellulose ethers such as Hydroxy propyl methyl cellulose,
Hydroxy ethyl cellulose and Polyvinylpyrolidone having different  degree of solubility
and  swellability.  Lactose  was  included  as  diluent.  Ethyl  cellulose  was  selected  as  a
backing material because this hydrophobic polymer has very low water permeability thus
providing an impermeable backing layer that prevents drug loss. 
FTIR spectral analysis showed that there was no appearance or disappearance of
any characteristic peak, which confirms the absence of chemical interaction between drug
and polymers.
The blend of ingredients was analyzed for their physical characteristics. The angle
of repose of formulation blends F1 to F9 were in the range of 310  45' ±0.1210 to 340  02'
±0.4347. The bulk density, tapped density, Compressibility index and Hauser’ ratio were
found  in  0.316±0.0010  to  0.434±  0.0015  (gms/cc),  0.506±0.506  to  0.425±0.0066
(gms/cc), 19.280±1.201 to 13.760±1.021 and 1.238 ± 1.018 to 1.159± 0.013 respectively.
It reveals that all the formulation blends were having good flow characteristics and flow
rate.
All the formulations pass the test for weight variation as per IP standard ± 7.5 %
deviation.
Percentage of drug content for all formulations F1 to F9 were in the range of
99.01±0.56 to 96.95±0.20.
Thickness of F1-F9 formulations were found to be 3.49±0.005 to 3.21±0.010 mm.
Hardness  of  all  formulations  F1-F9  were  found  to  be  5.6  to  5.1  kg/cm2.  Percentage
friability of all  formulations F1-F9 were found to be 0.464 % to 0.0.361 %.
The bioadhesion and drug release profile are dependent upon swelling behavior of
the tablets .High swelling index values of the formulations suggests that a large surface
area is available for interaction. Swelling index was calculated with respect to time.
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The surface pH of all the formulations were found to be within neutral pH with
±1. Low surface pH caused damage to contacting mucosal surface, if  any surface pH
changes occurred. Buccal tablets of all the formulations surface pH values in the range of
7.1 to 6.5 were within the acceptable limit. That indicates no risk of buccal damage or
irritation in buccal cavity.           
Mucoadhesion of buccal compact increases significantly with increase in carpobol
concentration in the buccal layer. Increasing the concentration of carbopol 934 induced a
moderate  adhesion  stronger  than  increasing  concentration  of  HPMC,  HEC and  PVP.
Increasing carbopol concentration follows this order BATCH I > BATCH II > BATCH III
respectively. The almost same mucoadhesion profile were  seen with in all batch  of these
formulations.
The drug release was affected by the concentration of HPMC K100M, Hydroxy
ethyl cellulose, PVP. The concentration of carbopol 934P also controls the drug release.
Carbopol 934P is a more hydrophilic polymer, it can swell rapidly. Therefore, decreasing
of carbopol content delays the drug release. Although, HPMC K100M, Hydroxy ethyl
cellulose  and  PVP  has  low  bioadhesive  properties,  it  was  responsible  to  provide
atorvastatin calcium drug release approaching zero order kinetics from the dissolution
profile obtained and it was evident that the drug release rate was controlled.  
Finally, the drug permeation profiles were investigated for all the buccal tablets.
The  ex  vivo  permeation  studies  showed that  the  released  drug  permeates  the  buccal
membrane linearly.  
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10. CONCLUSION
The  bright  light  development  and  evaluation  of  directly  compressed
mucoadhesive buccal formulations of atorvastatin calcium showed excellent bioadhesive
properties with controlled release. The result of this study reveals that increasing the total
polymer  content  of  tablets  leads  to  decrease  in  the  rate  of  release.  By adjusting the
polymer grades and concentration it would be possible to control the release pattern with
providing excellent  bioadhesion at  the same time. The development of  mucoadhesive
buccal tablets of atorvastatin calcium is one of the alternative route of administration to
avoid first pass effect and provide controlled release .In future the in-vivo studies can be
recommended  for  the  directly  compressed  atorvastatin  calcium mucoadhesive  buccal
tablets.
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